Introduction {#s1}
============

The brain has a very high metabolic rate, but lacks a conventional lymphatic system for clearance of metabolites and waste products. It is thought that the movement of cerebrospinal fluid (CSF) plays an important role in removing these waste products ([@bib111]). CSF is constantly produced by the choroid plexus ([@bib32]), circulates through the subarachnoid space and into the brain via a periarterial route ([@bib57]), and then exits the brain via several routes ([@bib129]; [@bib86]; [@bib138]; [@bib98]). Normal aging is accompanied by decreases in CSF production and increases in CSF outflow resistance ([@bib84]; [@bib33]; [@bib31]). CSF turnover is disrupted in pathological conditions such as Alzheimer's disease (AD) and normal pressure hydrocephalus (NPH) ([@bib5]; [@bib69]; [@bib109]). The balance between CSF production and outflow plays a key role in setting and maintaining the intracranial pressure (ICP) ([@bib70]). Because CSF production is actively regulated to maintain normal ICP ([@bib82]), damage to the outflow pathways could drive compensatory decreases in CSF production and turnover ([@bib31]) or altered patterns of CSF flow. Either of these could result in decreased waste clearance, as is seen in aging and some neurological diseases.

While there are lymphatic vessels in the meninges ([@bib7]; [@bib78]), there is evidence in both humans and other mammals pointing to drainage of the CSF through the cribriform plate (CP) ([@bib138]; [@bib33]; [@bib127]; [@bib80]; [@bib14]; [@bib42]; [@bib134]; [@bib28]; [@bib131]; [@bib66]; [@bib13]; [@bib61]). The CP is a fenestrated bony plate of the ethmoid bone that separates the cranial and nasal cavities. Once through the plate, CSF is absorbed by lymphatic vessels in the nasal mucosa and drained into the cervical lymph nodes ([@bib15]). There has been speculation that interstitial fluid (ISF) and CSF leave the brain via the extracellular space between olfactory sensory nerve (OSN) axon bundles ([@bib117]), as the intercellular space between axon bundles provide low-resistance directed pathways for fluid flow ([@bib116]). Acute blockage of CSF outflow by surgically obstructing the CP results in an increase in resting ICP ([@bib87]) and outflow resistance ([@bib108]), providing evidence for a drainage role of the trans-CP pathway. Intriguingly, there may be a connection between the patency of the clearance pathway through the CP and neurodegenerative diseases ([@bib33]; [@bib43]). The neurons whose axons make up the nerve bundles that traverse the CP, OSNs, are exposed to environmental toxins (such as air pollutants \[[@bib3]\]), which epidemiological studies have associated exposure to neurodegenerative diseases. Furthermore, anosmia and decreased acuity in the sense of smell, which will result from OSN damage, reliably precede many neurological disorders ([@bib3]). Thus, damage to or decreases in the numbers of the OSN axons could increase the resistance to CSF outflow, triggering a downregulation in CSF production and turnover. However, a method to maintain the three-dimensional structure of the hard, calcified plate and traversing axons and soft tissues to visualize the microscopic anatomical basis of this movement has been lacking. To better understand the role of the CP CSF outflow pathway, we characterized the cellular anatomy of the structures that traverse the CP and explored the chronic effects of OSN ablation on CSF turnover. We also found that OSN ablation disrupted CSF drainage through the CP, but normal ICP was maintained.

Results {#s2}
=======

Macroscopic structure of the cribriform plate {#s2-1}
---------------------------------------------

We first examined the macroscopic anatomical structure of the mouse CP to elucidate any stereotyped anatomical structure of the calcified tissue. While the anatomy of the CP has been studied in humans ([@bib64]) and other large mammals, both extinct and extant ([@bib96]; [@bib9]; [@bib10]; [@bib11]), the structure of the mouse CP has not been as well characterized. To visualize the 3D anatomy of the calcified bone of the CP, skulls of adult mice (3 Swiss Webster and 3 C57BL/6J) were de-fleshed by dermestid beetles, and imaged with micro-CT. Reconstructed CT images from an example mouse are shown in [Figure 1A--C](#fig1){ref-type="fig"}, showing the typical morphology of the murine CP. Photographs of the CP after removing the caudal portion of the skull showed similar structure ([Figure 1D](#fig1){ref-type="fig"}). The side of the plate adjacent to the olfactory bulb was not planar, but rather convex to accommodate the rounded shape of the anterior ventral face of the olfactory bulbs ([Figure 1E](#fig1){ref-type="fig"}); consequently, thin sections (like those obtained using traditional histology) will only contain a fraction of the structure. We observed a calcified ridge along the midline of the CP (crista galli) with an irregular perforation pattern, with many small (\<200 µm diameter) foramina (holes). While the positioning, number, and size of the smaller foramina were variable across mice, there were four major foramen appearing in the same locations in all mice imaged. Bilateral foramina were located on the anterior aspect of the plate, lateral to the crista galli, and midway along the dorsal ventral axis of the CP on each side ([Figure 1C,D,F](#fig1){ref-type="fig"}). Their location and structure were consistent across all animals examined with micro-CT. To quantify the total area of all the foramina (see Materials and methods), maximum intensity projections were made along the axis perpendicular to the face of the plate ([Figure 1F](#fig1){ref-type="fig"}). We found the total area of the foramina was 1.88 ± 0.29 mm^2^ (mean ± std, n = 6, pooling both C57BL/6J and Swiss Webster mice) and the total area of the plate was 9.76 ± 1.12 mm^2^ (mean ± std, n = 6, pooling both C57BL/6J and Swiss Webster mice), similar to previous reports ([@bib11]). CT images with C57BL/6J and Swiss Webster mice showed similar CP morphology ([Figure 1---figure supplement 1A--D](#fig1s1){ref-type="fig"}), suggesting that for these two strains, there are minimal strain differences. While a significant difference in total plate area ([Figure 1G](#fig1){ref-type="fig"}) was observed between C57BL/6J (10.693 ± 0.374 mm^2^) and Swiss Webster mice (8.821 ± 0.607 mm^2^), no significant difference was observed for total foramina area ([Figure 1G](#fig1){ref-type="fig"}) or in the ratio of foramina area to plate area ([Figure 1H](#fig1){ref-type="fig"}). Because the bone is impermeable to fluid movement, these holes will be the only outlet for CSF flow through the CP, and the nature of the soft tissue filling them (olfactory nerves, blood vessels, or lymphatic vessels) will play an important role in directing the flow of CSF.

![Structure of the calcified tissue of the cribriform plate and its relationship to olfactory sensory neuron axons.\
For schematics: olfactory nerve (ON), neuroepithelium (NE), cribriform plate (CP), olfactory bulb (OB) and glomeruli (yellow circles). D = dorsal, R = rostral, M = medial, and L = lateral. (**A**) Sagittal view of a microCT scan of a mouse skull. Black planes bracket the area of the CP. (**B**) Anterior-looking view of the CP from microCT image. (**C**) Area indicated by purple box in (**B**). (**D**) Photograph of the CP from the same point of view as the CT reconstruction in (**C**). Scale bar 1 mm. **E**) Sagittal view of the OB and CP junction illustrating the curved structure of the CP. (**F**) Max intensity projection of a 1.67 mm thick section of the CP depicting the major foramina (yellow arrows) and crista galli (blue arrow). Scale bar 1 mm. (**G--H**) Mean ± standard deviation plotted. Circles and squares represent means of individual animals. (**G**) Left: Comparison of total foramina area between Swiss Webster and C57BL/6J mice: (t(4) = 1.32, p=0.256, n = 3 for each group, ttest2). Comparison of the total area of the CP between Swiss Webster and C57BL/6J mice: (t(4) = 4.55, p=0.021, n = 3 for each group, ttest2). (\*p≤0.05). (**H**) Comparison of the ratio of the foramina area and CP area between Swiss Webster and C57BL/6J mice: (t(4) = 0.3891, p=0.7170, n = 3 for each group, ttest2). (**I**) Schematic of the sagittal plane of the mouse skull and brain showing the relationship of the OB and nerve junction to the CP. (**J**) Sagittal view of the area within the pink box in (**I**), depicting OSNs crossing the CP and terminating in the OB and glomeruli. (**K**) Coronal view of the black dashed line in (**I**) illustrating the location of the CP relative to the OBs and NE. (**L--M**) Immunofluorescent staining, OMP (red) and DAPI (blue). Scale bars 250 μm. (**L**) Sagittal plane, area depicted in (**J**), showing the two main OSN axon bundles (yellow arrows) that pass through the major foramina of the CP. (**M**) Coronal plane, area indicated in (**K**), showing OSN axon bundles that traverse the minor foramina of the CP along the crista galli.](elife-44278-fig1){#fig1}

Olfactory nerves enter through the primary foramina {#s2-2}
---------------------------------------------------

We then asked which foramina in the CP were traversed by OSN axons. However, the junction of the olfactory bulb and nerves is difficult to visualize histologically since the calcified CP, which the OSNs pass through, is immediately adjacent to the soft brain. To maintain the spatial alignment between the soft tissue and CP during sectioning, the bones of the skull must first be softened by decalcification. Traditional decalcification techniques require soaking the tissue in EDTA for several weeks ([@bib4]; [@bib91]), which results in degradation of epitopes, making it incompatible with immunohistochemistry. We developed a rapid decalcification protocol using formic acid (see Materials and methods), allowing us to decalcify the skull within 2 days, thereby preserving epitopes for immunohistochemical labeling. Using formic acid decalcification, we were able to section the skull in a way that maintained the pathway of the OSNs (labeled with an anti-olfactory marker protein (OMP) antibody \[[@bib18]; [@bib41]\]) traversing the CP ([Figure 1L--M](#fig1){ref-type="fig"}). OMP-expressing OSN axon bundles were observed traversing the CP and synapsing onto the olfactory bulb ([Figure 1L,M](#fig1){ref-type="fig"}), with two major axon bundles (yellow arrows) on the left and right sides ([Figure 1L](#fig1){ref-type="fig"}). These OSN axon bundles filled the four major foramen observed in the CP ([Figure 1C,D,F](#fig1){ref-type="fig"}). In the coronal plane, smaller axon bundles traversed the CP through the smaller foramina bordering the crista galli ([Figure 1M](#fig1){ref-type="fig"}). These results show that there are two distinct types of foramen in the CP: the major foramen, through which the larger OSN bundles pass through, and a multitude of smaller holes whose position varied across animals and some of which carried smaller OSN bundles. Because extracellular fluid flow preferentially moves parallel to axon tracts ([@bib116]), these nerves can provide directed conduits for CSF to move from the cranial cavity into the nasal cavity.

Blood vessels traverse the cribriform plate {#s2-3}
-------------------------------------------

We then asked what other soft tissues were contained within the small foramen, as the nature of these tissues will influence the flow of fluid out of the cranial compartment. The presence of blood and lymphatic vessels in the foramina were assessed because both tissue types could be conduits for fluid flow ([@bib57]; [@bib7]; [@bib78]).

We first looked at whether blood vessels traversed the CP by either filling the vessel lumen with FITC-albumin ([@bib121]), or labeling the endothelial cells by perfusing the vasculature with the fluorescent lipophilic dye DiI ([@bib75]). Note that we cannot distinguish between arteries and veins using these methods. FITC-albumin filled vessels were found to run parallel to the OSNs traversing the CP ([Figure 2D--E](#fig2){ref-type="fig"}). Blood vessels, labeled by DiI, were also clearly visible in the smaller foramina ([Figure 2M--O](#fig2){ref-type="fig"}). Both olfactory nerve bundles and blood vessels were present in other foramina ([Figure 2M](#fig2){ref-type="fig"}). These results are consistent with previous work showing blood vessels traverse the CP in the rodent ([@bib77]), much like the ethmoidal arteries and veins observed in humans ([@bib77]; [@bib67]; [@bib136]; [@bib114]; [@bib122]; [@bib123]), linking the vascular territories of the nasal epithelia and brain.

![Aquaporin 1 and blood vessels are present in the cribriform plate and olfactory nerve junction.\
For schematics: olfactory nerve (ON), neuroepithelium (NE), cribriform plate (CP), olfactory bulb (OB) and glomeruli (yellow circles). D = dorsal, R = rostral, M = medial, and L = lateral). (**A**) Schematic of the sagittal plane of the mouse skull and brain showing the relationship of the OB and nerve junction to the CP. (**B**) Sagittal view of the area within the pink box in (**A**), depicting OSNs crossing the CP and terminating in the OB and glomeruli. (**C**) Coronal view of the black dashed line in (**A**) illustrating the location of the CP relative to the OBs and NE. **D**) Area depicted by the pink box in (**A**), showing the presence of FITC-albumin filled blood vessels (white) along the medial ON. (**E**) Magnified area of (**D**). (**F--O**) Immunofluorescent staining, OMP (red), AQP1 (green), AQP4 (purple), DiI (white), and DAPI (blue). (**F--G**) Area depicted by the pink box in (**A**), showing the expression of AQP1 (**F**) at the junction of the OB and medial ON and in the lamina propria of the NE. (**H--I**) Area depicted by the orange box in (**A**), showing the expression of AQP1 at the junction of the OB and lateral ON and in the lamina propria of the NE. (**J--K**) Magnified area of (**H--I**). (**L**) AQP1 expression, in the area indicated in (**C**), is present in the lining of the smaller foramina along the midline of the crista galli, on the olfactory nerve layer of the OB, and in the lamina propria of the NE. (**M--O**) DiI-labeled endothelial cells of blood vessels traversing the smaller foramina of the CP alongside ONs (**M**) and lined with AQP-1 (**N--O**) or AQP-4 (**O**), area indicated by purple box in (**C**). (**D, F--I, L**) Scale bars 250 μm. (**E, J--K, M--O**) Scale bars 50 μm.](elife-44278-fig2){#fig2}

Aquaporins at the olfactory nerve-bulb interface {#s2-4}
------------------------------------------------

Aquaporins (AQP) greatly enhance the permeability of cells to water ([@bib118]), and their presence would help facilitate the movement of fluid down the pressure gradient. The different aquaporin protein subtypes have similar structure, but differ in their localization throughout the body ([@bib118]). We used immunofluorescence to examine the expression of aquaporin channels at the interface between the CP and olfactory bulbs. We validated each antibody using mouse kidney tissue, except the AQP4 antibody was validated in the cortex ([Figure 2---figure supplement 1L--O](#fig2s1){ref-type="fig"}) ([@bib126]; [@bib103]; [@bib99]). We first looked at the expression of aquaporin-1 (AQP1), as it has been shown that expression of AQP1 in the CNS begins early ([@bib60]; [@bib132]), and is required in adulthood to maintain CSF production by the choroid plexus ([@bib93]). Interestingly, previous work has also shown that AQP1 is expressed along the periphery of the olfactory bulb in neonatal mice ([@bib105]), and there are high levels of expression of AQP1, 3, and 5, within the nasal cavity ([@bib1]). The junction of the olfactory bulb and nerve is a prime exit route for CSF into the nasal cavity. Expression of aquaporins in this area would facilitate the flow of fluid out of the olfactory bulb and subarachnoid space, into the nasal cavity (via OSNs). We observed high levels of AQP1 expression on the olfactory nerve layer down to the glomeruli, as observed previously ([@bib105]), and in the lamina propria of the neuroepithelium at both the medial ([Figure 2F--G](#fig2){ref-type="fig"}) and dorsal ([Figure 2H--K](#fig2){ref-type="fig"}) junctions of the olfactory bulb and nerve. AQP1 was also observed lining the foramina of the CP along the crista galli ([Figure 2L,N--O](#fig2){ref-type="fig"}) but did not co-label with Vimentin-positive fibroblasts ([Figure 2](#fig2){ref-type="fig"} -- figure supplement J-K). Based on previous reports ([@bib8]; [@bib72]) and our own results, we hypothesize that these AQP1-expressing cells might be olfactory ensheathing cells (OECs). High levels of AQP1 expression were not seen in any other brain area, with the exception of the choroid plexus ([@bib60]) strongly suggesting the interface between the olfactory nerve and bulb is a brain region with a high fluid flux flowing through it.

We then examined the expression of AQP4, which is enriched around astrocyte endfeet in the cortex ([@bib92]) and is hypothesized to play a role in transport of fluid through the glymphatic system ([@bib57]) (though this is controversial \[[@bib112]\]). We observed expression of AQP4 in GFAP-positive astrocytes in the cortex ([Figure 2](#fig2){ref-type="fig"} -- figure supplement L-M) and within the olfactory nerve and neuroepithelium ([Figure 2---figure supplement 1F--G](#fig2s1){ref-type="fig"}). The localization of other aquaporins, AQP2, AQP3, and AQP5, were also examined at the olfactory bulb and nerve junction, but their expression was limited to the neuroepithelium and CP ([Figure 2---figure supplement 1D--E,H--I](#fig2s1){ref-type="fig"}). The highly enriched expression of aquaporins observed in the tissues at the junctional area of the olfactory nerve and bulb could provide a low-resistance pathway for fluid to pass from the olfactory bulb to the olfactory nerves, out of the cranium, and ultimately into the nasal cavity.

Lymphatic vessels traverse the cribriform plate {#s2-5}
-----------------------------------------------

Lymphatic vessels play a role in moving fluid throughout the body and are found in the meninges ([@bib7]; [@bib78]) and nasal epithelium ([@bib61]). Lymphatic vessels crossing the CP could play a role in transporting fluid from the cranial cavity to the nasal cavity. We used LYVE1-GFP (lymphatic vessel endothelial hyaluronan receptor 1) or LYVE1-tdTomato mice (see Materials and methods) to visualize lymphatic vessels. To verify that the LYVE1-GFP or LYVE1-tdTomato transgene was not expressed in vascular endothelial cells, the mice were perfused using either DiI or FITC-albumin, respectively, and the cervical lymph nodes were examined to detect cross-labeling ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}). Expression of *LYVE1* was observed in the dural lymphatics, while minimal cross-labeling with fluorescent dye (rhodamine) conjugated to phalloidin (which will preferentially label F-actin of arteries \[[@bib133]\]) was observed ([Figure 3---figure supplement 1C--D](#fig3s1){ref-type="fig"}). Surprisingly, we observed blood vessel (identified by FITC-albumin fills) endothelial cells that expressed *LYVE1* throughout the brain ([Figure 3---figure supplement 1F--G](#fig3s1){ref-type="fig"}). We also observed non-lymphatic cells of an unknown type in the frontal cortex expressing *LYVE1* ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) that were GFAP, NeuN, Oligo1, and CD164 negative ([Figure 3---figure supplement 2B--E,H--M](#fig3s2){ref-type="fig"}). However, they were occasionally MRC1 (mannose receptor 1) positive ([Figure 3---figure supplement 2F--G](#fig3s2){ref-type="fig"}), CD31 (PE-CAM) positive ([Figure 3---figure supplement 2N--O](#fig3s2){ref-type="fig"}), or expressed in the smooth muscle of arteries and capillaries ([Figure 3---figure supplement 2P--Q](#fig3s2){ref-type="fig"}). Interestingly, we found a few LYVE1^+^ vessels (both DiI and FITC-albumin negative) adjacent to OSNs in the nasal cavity ([Figure 3D--G](#fig3){ref-type="fig"}), lining holes in the lamina propria of the neuroepithelium, and traversing the CP ([Figure 3H--K](#fig3){ref-type="fig"}). Although *LYVE1* is not expressed exclusively in lymphatic vessels, these results demonstrate that LYVE1^+^ lymphatic vessels traverse the CP and could facilitate the movement of fluid from the brain compartment to the nasal compartment.

![Localization of lymphatic vessels at the cribriform plate and olfactory bulb junction.\
For schematics: olfactory nerve (ON), neuroepithelium (NE), cribriform plate (CP), olfactory bulb (OB) and glomeruli (yellow circles). D = dorsal, R = rostral, M = medial, and L = lateral. (**A**) Schematic of the sagittal plane of the mouse skull and brain showing the relationship of the OB and nerve junction to the CP. (**B**) Sagittal view of the area within the pink box in (**A**), depicting OSNs crossing the CP and terminating in the OB and glomeruli. (**C**) Coronal view of the black dashed line in (**A**) illustrating the location of the CP relative to the OBs and NE. (**D--K**) Immunofluorescent staining: LYVE1 (magenta), FITC-albumin (green), and DAPI (blue) in LYVE1-tdtomato mice. (**D--E**) Localization of LYVE1^+^ vessels along the medial olfactory nerve, sagittal area indicated in (**B**), depicting LYVE1^+^/FITC-albumin negative vessels (putative lymphatic vessels) running parallel to the olfactory nerve. (**F--G**) Area indicated by green box in (**B**), magnified area of (**D--E**). (**H**) Localization of LYVE1^+^ vessels in the nasal epithelium and traversing the CP, coronal area indicated in (**C**). (**I**) Area indicated by purple box in (**C**), magnified area of (**H**), depicting LYVE1^+^ vessels traversing foramina of the CP. (**J**) Localization of LYVE1^+^ vessels and blood vessels (labeled with FITC-albumin) in the nasal epithelium and traversing the CP, coronal area indicated in (**C**). (**K**) Area indicated by purple box in (**C**), magnified area of (**H**), depicting only blood vessels (labeled with FITC-albumin) traversing foramina of the CP. (**D--E, H, J**) Scale bars 250 μm. (**F--G, I, K**) Scale bars 50 μm.](elife-44278-fig3){#fig3}

Visualization of CSF flow through the cribriform plate {#s2-6}
------------------------------------------------------

To visualize CSF flow in the regions downstream from the cisterna magna, we injected the high-contrast Evans blue (EB) ([@bib128]; [@bib81]; [@bib51]; [@bib74]) dye into the cisterna magna ([Figure 4A](#fig4){ref-type="fig"}). When injected into the blood stream, EB binds to albumin in the plasma making it a high-molecular-weight tracer. However, protein concentrations are vastly lower in the CSF ([@bib100]), so most EB will be unattached to proteins and function as a low molecular weight tracer, freely transported by fluid convection (See Materials and methods for calculations). Injected heads were then decalcified and cut along the midline for imaging as described above ([Figure 4B,D](#fig4){ref-type="fig"}). EB was not observed within the sagittal sinus or the parenchyma, consistent with EB not crossing the glia limitans. Dye was restricted to the subarachnoid space around the brain and spinal column ([Figure 4B--C](#fig4){ref-type="fig"}) and was also clearly visible in the nasal epithelium and the deep cervical lymph nodes ([Figure 4E](#fig4){ref-type="fig"}). To quantify dye movement down the spinal columns, spinal columns were decalcified and cleared using SeeDB ([@bib65]; [@bib52]) ([Figure 4C](#fig4){ref-type="fig"}). Cardiac perfusion had no qualitative effect on EB movement, as EB was present in the nasal epithelia even without perfusion. The observed pathways of CSF (EB dye) flow and drainage through the CP, into the deep cervical lymph nodes, and along the spinal column, are consistent with previous work using radiolabeled tracers, latex fills, and other tracers ([@bib14]; [@bib61]; [@bib29]; [@bib97]; [@bib54]). We also injected 3kDa-FITCDextran into the cisterna magna to visualize CSF flow and drainage ([Figure 5B--C](#fig5){ref-type="fig"}). To determine the anatomic route of the dye, 3kDa-FITCDextran was injected directly into the olfactory bulb. The tracer appeared to be travelling along perivascular space vessels found in the olfactory nerve bundle and the extracellular space. No co-localization of CSF tracers with OMP or β3-tubulin (both label olfactory sensory axons) were observed in the olfactory nerves ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). To determine the role of LYVE1^+^ vessels in CSF clearance in the nasal cavity, LYVE1-tdTomato (Ai14) mice were injected with 3kDa-FITCDextran in the cisterna magna ([Figure 5D--I](#fig5){ref-type="fig"}). 3kDa-FITCDextran was observed draining into the nasal cavity along the olfactory nerve ([Figure 5D--F](#fig5){ref-type="fig"}), and co-localizing with LYVE1^+^ vessels along the olfactory nerve ([Figure 5G--I](#fig5){ref-type="fig"}), although the dye did not appear to be concentrated in the LYVE1^+^ vessels. These results show that CSF exits the cranial cavity through the CP and is absorbed by nasal LYVE1^+^ (putatively lymphatic) vessels.

![Visualization of CSF flow into the nasal cavity and spinal column by injection of Evans blue dye into the cisterna magna.\
(**A**) Schematic of the sagittal plane of the mouse skull and brain depicting the flow of CSF (blue arrows) and location of EB injection into the cisterna magna. (**B**) Sagittal, midline cut of a decalcified skull and spinal column after a cisterna magna EB injection. Scale bar 3 mm. (**C**) A decalcified and SeeDB-cleared spinal column (cut between C2 and C3, with C3 at the top of the picture) after a cisterna magna EB injection. Scale bar 2 mm. **D**) Area depicted by pink box in (**A**), showing drainage of EB dye across the CP into the nasal cavity. Scale bar 1 mm. (**E**) Localization of EB dye in the deep cervical lymph nodes (purple arrows) after a cisterna magna EB injection. Scale bar 1 mm.](elife-44278-fig4){#fig4}

![Visualization of CSF flow into the nasal cavity by injection of 3kDa-FITCDextran into the cisterna magna.\
(**A**) Schematic of the sagittal plane of the mouse skull and brain depicting the flow of CSF (blue arrows) and location of 3kDa-FITCDextran injection into the cisterna magna. (**B--I**) Fluorescent images of a mouse skull and brain 35 min after a 3kDa-FITCDextran (green) cisterna magna injection. (**B**) Skull outlined by white dashed lines. 3kDa-FITCDextran is observed in the cisterna magna and the nasal cavity. (**C**) Area indicated by pink box in (**A**). FITC 3kD-Dextran is observed in the nasal cavity. Scale bar 500 μm. (**D--I**) Fluorescent images of a mouse skull and brain 35 min after a 3kDa-FITCDextran (green) cisterna magna injection into a LYVE1-tdTomato (Ai14) mouse. LYVE1 (magenta) and DAPI (blue). (**D--F**) Area indicated by white box in (**C**). 3kDa-FITCDextran is observed draining into the nasal cavity along the olfactory nerve. LYVE1^+^ vessels are observed running parallel to the olfactory nerve. Scale bar 250 μm (**G-I**) Area indicated by white box in (**F**). 3kD-FITCDextran is observed moving along and through LYVE1^+^ vessels. Scale bar 50 μm.](elife-44278-fig5){#fig5}

Chemical ablation of olfactory sensory nerves {#s2-7}
---------------------------------------------

We then asked if ablation of OSNs, which removes the low-resistance pathway for fluid flow through the CP, might also block movement of CSF through the CP. Previous work has shown that intranasal treatment of ZnSO~4~ causes the rapid death of OSNs, and persists for months ([@bib19]; [@bib85]; [@bib115]). To chemically ablate OSNs, mice were briefly anaesthetized with isoflurane, and an intranasal solution of ZnSO~4~ (10% in sterile H~2~O) or vehicle (sterile H~2~O) was administered to the left nare. Because a loss of the olfactory nerve layer and overall reduction in the size of the olfactory bulb indicates successful ablation of OSNs by ZnSO~4~ ([@bib19]), we measured the size of the olfactory bulb 2, 10, and 30 days after zinc treatment. A significant decrease in olfactory bulb area was observed compared to vehicle controls 10 days (t(12) = 6.46, p≤0.001, n = 14 (7 each group), ttest2) and 30 days (t(12) = 6.712, p≤0.001, n = 7 for each group, ttest2) after treatment ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Mice treated with ZnSO~4~ exhibited weight loss initially after treatment, but then began gaining weight at a normal rate starting one week later ([Figure 6A](#fig6){ref-type="fig"}). Running wheels (Med Associates Inc, Fairfax, VT) were placed in the cages of individually-housed mice ([Figure 6B](#fig6){ref-type="fig"}) to quantify activity levels before and after treatment. ZnSO~4~ treatment had minimal effects on running behavior ([Figure 6C--D](#fig6){ref-type="fig"}), compared to vehicle controls. These results show that chemical ablation of OSNs with ZnSO~4~ had minimal effects on the overall health and behavior of the mice.

![Effects of ZnSO~4~ treatment on behavior and olfactory sensory nerve axons.\
(**A**) Percent weight loss of vehicle (blue) and ZnSO~4~ treated (black) mice after treatment. There was a significant difference in weight of ZnSO~4~-treated mice compared to control mice 1 week (p=0.001, n = 17 for vehicle and n = 25 for treated, ttest2) and 4 weeks (p=0.004, n = 17 for vehicle and n = 25 for treated, ttest2) after treatment. Mean ± standard deviation plotted. \*\*p≤0.01 \*\*\*p≤0.001 (**B**) Photo of a Swiss Webster mouse on the running wheel. (**C**) Actogram of the activity of a single mouse before and after ZnSO~4~ treatment. Treatment time indicated by pink line. (**D**) Individual counts of total wheel activity per day (vehicle = blue, ZnSO~4~treated = gray), bold line is the mean of each group. No significant difference observed between groups (p=0.5189, KSTAT = 0.3750, n = 8 for each group, K-S test). (**E**) Schematic: sagittal plane depicting OSNs crossing the CP and synapsing onto the OB and glomeruli (yellow circles). (**F--M**) Immunofluorescent staining of area depicted in (**E**), OMP (red), LYVE1 (magenta) and DAPI (blue). Scale bar 250 μm. (**F, J**) Vehicle Control. (**G, K**) Two days after ZnSO~4~ treatment. (**H, L**) Ten days after ZnSO~4~ treatment. (**I, M**) Thirty days after ZnSO~4~ treatment. Swiss Webster mice were used for (**F--I**) and LYVE1-GFP (Ai6) mice were used for (**J--M**). (**N**) Quantification of OMP signal fluorescence for vehicle (n = 14) mice compared to 2 (t(8) = 0.1429, p=0.8898, n = 5, post-hoc ttest2), 10 (t(13) = 15.71, p≤0.001, n = 8, post-hoc ttest2) and 30 (t(13) = 25.39, p≤0.001, n = 9, post-hoc ttest2) days after ZnSO~4~ treatment. Mean ± standard deviation plotted. Circles, triangles, and squares represent means of individual animals. \*\*\*p≤0.001.](elife-44278-fig6){#fig6}

The olfactory marker protein (OMP) antibody was utilized to histologically examine OSN damage ([Figure 6F--I](#fig6){ref-type="fig"}). Two days after ZnSO~4~ treatment ([Figure 6G](#fig6){ref-type="fig"}), we observed the beginnings of degeneration of the olfactory nerves. Ten days after ZnSO~4~ treatment ([Figure 6H](#fig6){ref-type="fig"}), we observed a profound loss of OSN axons, and 30 days after treatment, a complete loss of OSNs traversing the CP from the nasal epithelium was observed ([Figure 6I](#fig6){ref-type="fig"}). We quantified the OMP fluorescent signal intensity in the ZnSO~4~-treated and vehicle mice ([Figure 6N](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). A significant decrease in OMP signal was observed in the treated animals compared to the vehicle controls (F(3, 32)=259.5, p≤0.001, n = 14 for vehicle, n = 5 for 2 day, n = 8 for 10 day, and n = 9 for 30 day, one-way ANOVA). These results show that OSNs have largely degenerated 10 days after treatment and are absent a month after intranasal ZnSO~4~ treatment. As a check for any strain-dependent differences, ZnSO~4~ treatment was also performed in C57BL/6J mice. Both C57BL/6J and Swiss Webster mice were treated with ZnSO~4~ (or vehicle control) and histologically examined using Nissl-thionin staining 30 days after treatment ([Figure 6---figure supplement 1C--F](#fig6s1){ref-type="fig"}), showing similar effects.

We then assayed mRNA levels in the choroid plexus and GFAP expression in the cortex to look for immune responses to ZnSO~4~ treatment. AQP1, expressed by epithelial cells in the choroid plexus, is involved in CSF production ([@bib93]). Klotho is a protein involved in suppressing aging and is significantly elevated in the CSF of Alzheimer's disease patients ([@bib73]; [@bib104]). The NF-κβ pathway is involved in the choroid plexus acute-phase response to peripheral inflammation ([@bib83]), and RelA is required for NF-κβ activation ([@bib26]). GFAP is an astrocytic marker and is upregulated as part of an inflammatory response ([@bib113]). However, we found no appreciable changes in mRNA levels or GFAP expression ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}) 2 or 10 days after ZnSO~4~ treatment, indicating there is no inflammatory response in the cranial cavity following treatment.

We then asked if nasal lymphatic vessels were damaged by the ZnSO~4~ treatment. If lymphatic vessels are a conduit for fluid flow, then damage by ZnSO~4~ would impede outflow. To detect any changes in lymphatic vessel number or morphology, we histologically examined LYVE1-GFP (Ai6) mice 2, 10, and 30 days after treatment, compared to vehicle controls ([Figure 5J--M](#fig5){ref-type="fig"}). We found no significant change in *LYVE1* expression or localization 2 days after ZnSO~4~ treatment in LYVE1-GFP mice ([Figure 5K](#fig5){ref-type="fig"}), however, a change in localization at 10 and 30 days after treatment was observed ([Figure 5L--M](#fig5){ref-type="fig"}). These results show that ZnSO~4~ treatment ablates OSNs while not affecting neighboring lymphatic vessel density in the CP area.

Ablation of OSNs decreases CSF outflow {#s2-8}
--------------------------------------

Because the space between the OSN axons provides a conduit for the outflow of CSF, removing these axons should decrease outflow of CSF. To visualize any disruption of CSF drainage through the CP after OSN ablation, we injected EB into the cisterna magna ([Figure 7A,C,D](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}) of mice treated with ZnSO~4~ and vehicle controls ([Figure 7B](#fig7){ref-type="fig"}). Then the mouse was perfused 10 min after the end of the dye infusion. We quantified the average intensity of EB along the rostral-caudal axis within a region of interest (ROI) that encompassed the olfactory bulb and nasal epithelia (see Materials and methods) ([Figure 7B--H](#fig7){ref-type="fig"}). Decreased flow of CSF through the CP would appear as a caudal-shift (leftward-shift) in the dye intensity curve. We plotted the average intensity of dye along the rostral-caudal axis for vehicle and ZnSO~4~-treated animals, for both the ipsilateral ([Figure 7H](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1B--E](#fig7s1){ref-type="fig"}) and the contralateral ([Figure 7---figure supplement 1F--J](#fig7s1){ref-type="fig"}) sides of treatment. We quantified dye movement using the center of mass along the anterior-posterior axis ([Figure 7I](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1K](#fig7s1){ref-type="fig"}), the peak location along the anterior-posterior axis ([Figure 7J](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1L](#fig7s1){ref-type="fig"}), and the peak value ([Figure 7K](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1M](#fig7s1){ref-type="fig"}) of the dye intensity. We found that 10 and 30 days after treatment, the peak location and center of mass of the dye curve was shifted caudally in ZnSO~4~-treated mice, relative to vehicle controls, indicating that CSF outflow through the CP was decreased by OSN ablation. For the side ipsilateral to treatment, we saw significant interactions between the effects of time after treatment and the treatment type (ZnSO~4~ or vehicle) on the center of mass location ([Table 1](#table1){ref-type="table"}). We also saw significant effects on the center of mass and the anterior-posterior peak location by both the duration of treatment and the type of treatment ([Table 1](#table1){ref-type="table"}). Next, to compare the amount of EB collected in the deep cervical lymph nodes after a cisterna magna injection between zinc- and vehicle-treated mice, the volume of EB injected (2 µL to 4.5 µL) and subsequently the duration of infusion was increased to 45 min. No difference in EB collected in the deep cervical lymph nodes was observed between vehicle- ([Figure 8B](#fig8){ref-type="fig"}) and zinc-treated ([Figure 8C](#fig8){ref-type="fig"}) mice 30 days after treatment. Interestingly, the decrease in CSF outflow through the CP in zinc-treated mice, compared to vehicle mice, was still observed 30 days after treatment ([Figure 8D--E](#fig8){ref-type="fig"}), despite the increases in infusion volume and duration. While a significant caudal shift was observed in the center of mass of the EB dye peak, no difference was observed in the dye peak location ([Figure 8F--G](#fig8){ref-type="fig"}) or the distance dye traveled along the spinal column ([Figure 8H](#fig8){ref-type="fig"}). To confirm that this decrease of outflow was not due to some unique aspect of EB, we repeated these experiments by injecting 5 µL of 10% 3kDa-FITCDextran into the cisterna magna. For 3kDa-FITCDextran infusions, an infusion rate of 0.2 µL/min, was used and the animals were euthanized 10 min after the end of the infusion. A significant decrease in outflow of 3kDa-FITCDextran into the nasal cavity in ZnSO~4~-treated mice, relative to vehicle controls, was also observed ([Figure 9](#fig9){ref-type="fig"}). Thus, ablating OSNs blocks CSF outflow through the CP, and this blockage persists for a least a month.

![ZnSO~4~ treatment decreases CSF outflow through the cribriform plate ipsilateral to treatment.\
(**A**) Sagittal view schematic depicting direction of CSF flow and location of a cisterna magna injection of Evans blue. (**B--D**) Sagittal view of decalcified and cut skull for imaging after Evans blue injection, area indicated by pink box in (**A**). ROI indicated by blue box. Scale bar 1 mm. (**B**) Vehicle control. (**C**) 10 days after ZnSO~4~ treatment. (**D**) 30 days after ZnSO~4~ treatment. (**E--G**) Plot of the intensity of the Evans blue dye as a function rostral-caudal distance. (**E**) Vehicle control, ROI of area measured indicated by blue box in (**B**). (**F**) 10 day ZnSO~4~ treated, ROI of area measured indicated by blue box in (**C**). (**G**) 30 days after ZnSO~4~ treatment, ROI of area measured indicated by blue box in (**D**). (**H**) Comparison of all dye curves of all vehicle- (gray) and ZnSO~4~-treated (purple) groups for each time point after treatment: 2 day, n = 3 vehicle and n = 5 treated. 10 day, n = 5 for each group. 30 day, n = 6 vehicle and n = 11 for treated. Means plotted as bold lines. (**I--K**) Mean is plotted as height of bar. Circles represent individual animals. (**I**) Mean of the center of mass location of the dye curve plotted for vehicle- and ZnSO~4~-treated animals 2 (t(6) = 0.7489, p=0.4822, n = 3 vehicle and n = 5 treated, post-hoc ttest2), 10 (t(15) = −4.4921, p=0.0004, n = 5 for each group, post-hoc ttest2), and 30 ((t(15) = −3.7539, p=0.0019, n = 6 vehicle and n = 11 for treated, post-hoc ttest2) days after treatment. **J**) Mean dye peak location plotted for vehicle and ZnSO~4~-treated animals 2 (t(6) = −1.5082, p=0.1822, n = 3 vehicle and n = 5 treated, post-hoc ttest2), 10 (t(15) = −2.8064, p=0.0133, n = 5 for each group, post-hoc ttest2), and 30 (t(15) = −3.0014, p=0.0089, n = 6 vehicle and n = 11 for treated, post-hoc ttest2) days after treatment. (**K**) Maximum dye peak value plotted for vehicle and ZnSO~4~-treated animals 2 (t(6) = −1.4187, p=0.2058, n = 3 vehicle and n = 5 treated, post-hoc ttest2), 10 (t(15) = 0.7982, p=0.4372, n = 5 for each group, post-hoc ttest2), and 30 (t(15) = 0.2052, p=0.8402, n = 6 vehicle and n = 11 for treated, post-hoc ttest2) days after treatment. \*p≤0.05 \*\*p≤0.01. \*\*\*p≤0.001.](elife-44278-fig7){#fig7}

![Longer-duration dye injections show ZnSO~4~ treatment blocks CSF flow across the cribriform plate.\
(**A**) Sagittal view of the skull depicting direction of CSF flow and location of cisterna magna injection of EB. (**B--C**) Localization of EB dye in the deep cervical lymph nodes (orange circles) after a cisterna magna EB injection. Scale bar 500 µm. (**B**) Vehicle control. (**C**) 30 days after ZnSO~4~ treatment. (**D--E**) Sagittal view of decalcified and cut skull of the ipsilateral side for imaging after EB injection in the cisterna magna. ROI indicated by orange box. Scale bar 1 mm. (**D**) Vehicle control. (**E**) 30 days after ZnSO~4~ treatment. (**F**) Plot of the intensity of the Evans blue dye as a function rostral-caudal distance for vehicle (gray) and ZnSO~4~-treated (blue) groups 30 days after treatment. ROI indicated by orange box in (**D--E**). (**G**) Mean of the center of mass (t(10) = −3.2015, p=0.0095, n = 5 vehicle and n = 7 treated, post-hoc ttest2) and dye peak (t(10) = −1.6604, p=0.1278, n = 5 vehicle and n = 7 treated, post-hoc ttest2) location of the curve plotted for vehicle- and ZnSO~4~-treated animals 30 days after treatment. (**H**) Vehicle (top) and 30 days after ZnSO~4~ treatment (bottom) decalcified and SeeDB cleared spinal columns after cisterna magna EB injection. Scale bar 500 mm.](elife-44278-fig8){#fig8}

![Visualization of effects of intranasal ZnSO~4~ treatment on CSF flow with 3kDa-FITC Dextran.\
(**A**) Schematic of a sagittal view of the skull, depicting direction of CSF flow and location of cisterna magna injection of 3kDa-FITCDextran. (**B--C**) Sagittal view of decalcified and cut skull for imaging after FITC-dextran injection, area indicated by pink box in (**A**). Scale bar 500 µm. (**B**) Vehicle control. (**C**) 10 day ZnSO~4~ treated. (**D--E**) Plot of the intensity of the 3kDa-FITC Dextran dye as a function of rostral-caudal distance. (**D**) Vehicle control, ROI of area measured indicated by white box in (**B**). (**E**) 10 days after ZnSO~4~ treatment, ROI of area measured indicated by white box in (**C**). (**F--G**) Mean ± standard deviation plotted. Circles and squares represent means of individual animals. (**F**) Comparison of the center of mass location of the dye peak between the vehicle (black) and ZnSO~4~ (orange) treated groups (t(12) = −3.1805, p=0.0079, n = 6 vehicle and n = 8 treated, post-hoc ttest2). (**G**) Comparison of the location of the dye peak between the vehicle (black) and ZnSO~4~ (orange) treated groups (t(12) = −3.5384, p=0.0041, n = 6 vehicle and n = 8 treated, post-hoc ttest2). \*\*p≤0.01. Note that the time between cisterna magna injection and sacrifice was different in the FITC-dextran and EB injections (35 vs. 20 min respectively) due to the different molecular weights of the dyes.](elife-44278-fig9){#fig9}
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###### Two-way ANOVA statistics for all Evans blue cisterna magna injections.

d.o.f. = degrees of freedom. CoM = center of mass, PL = peak location, PV = peak value. All significant p values are bolded (p≤0.05).

  Evans blue drainage                                           
  --------------------- ----- -------------- ---------- ------- ---------------------------------
  *5.45*                *2*   ***0.0086***   *IPSI*     *CoM*   *Interaction: duration \* type*
  0.49                  2     0.6144         IPSI       PL      Interaction: duration \* type
  0.61                  2     0.5494         IPSI       PV      Interaction: duration \* type
  *11.05*               *2*   ***0.0002***   *IPSI*     *CoM*   *effect: duration*
  *13.16*               *1*   ***0.0009***   *IPSI*     *CoM*   *effect: type*
  *3.63*                *2*   ***0.0365***   *IPSI*     *PL*    *effect: duration*
  *13.72*               *1*   ***0.0007***   *IPSI*     *PL*    *effect: type*
  *5.27*                *2*   ***0.0098***   *IPSI*     *PV*    *effect: duration*
  0                     1     0.9497         IPSI       PV      effect: type
  1.06                  2     0.3601         CONTRA     CoM     Interaction: duration \* type
  2.08                  2     0.1435         CONTRA     PL      Interaction: duration \* type
  0.79                  2     0.4645         CONTRA     PV      Interaction: duration \* type
  2.93                  2     0.0694         CONTRA     CoM     effect: duration
  3.84                  1     0.0596         CONTRA     CoM     effect: type
  *4.19*                *2*   ***0.0253***   *CONTRA*   *PL*    *effect: duration*
  *10.64*               *1*   ***0.0028***   *CONTRA*   *PL*    *effect: type*
  0.73                  2     0.49           CONTRA     PV      effect: duration
  0.67                  1     0.4188         CONTRA     PV      effect: type

OSN ablation does not affect ICP {#s2-9}
--------------------------------

The production and outflow of CSF is dynamically balanced ([@bib82]) in such a way that an increase in outflow resistance will drive a rise in ICP ([@bib70]; [@bib63]), unless there is a compensatory reduction of CSF production or changes in the resistance of other outflow pathways. To test if the disruption of the nasal CSF outflow pathway causes a rise in ICP, we measured the ICP from awake, head-fixed mice ([@bib49]; [@bib47]). We implanted a titanium headbar and habituated the mice to head fixation on a spherical treadmill ([@bib48]), allowing them to voluntarily locomote. Locomotion is a natural behavior that causes vasodilation across the cortex ([@bib55]), which will increase ICP ([@bib34]). As a positive control, we also measured ICP in mice with cisterna magna injection of aCSF or kaolin ([Figure 10A](#fig10){ref-type="fig"}). Injections of kaolin into the cisterna magna are known to produce elevations in ICP, and are used to generate an animal model of hydrocephalus ([@bib12]). After mice were habituated to head fixation, kaolin or aCSF cisterna magna injections were performed. For ICP measurements, a small craniotomy was performed under isoflurane anesthesia and an ICP sensor (Millar SPR-1000) was placed \~1 mm into the cortex. Mice were allowed to wake up from anesthesia on a spherical treadmill, where ICP and treadmill motion were recorded. Data collection started at least 1 hr after the cessation of anesthesia to avoid the effects of anesthetics on ICP and other physiological processes ([@bib49]; [@bib47]; [@bib107]). We then measured ICP in mice intranasally treated with vehicle or ZnSO~4~, utilizing the same procedure for measuring ICP of the aCSF and kaolin injected mice ([Figure 10A](#fig10){ref-type="fig"}).

![Intranasal ZnSO~4~ treatment does not affect ICP but decreases CSF movement down the spinal column.\
(**A**) Left panel, example trace showing intracranial pressure (ICP) change during a locomotion bout in an animal that has been injected with aCSF in the cisterna magna. The ICP becomes elevated slightly over baseline when the animal moves, consistent with previous results ([@bib49]). The tick marks in the upper panel indicates locomotion events, defined as times where the treadmill acceleration exceeds a thereshold ([@bib55]). Subsequent panels show ICP change during locomotion in animals injected with Kaolin, vehicle control, or ZnSO~4~ treatment, respectively. (**B--D**) Mean ± standard deviation plotted. Circles represent individual animals. (**B**) Mean of each group of ICP during rest (1 hr after isoflurane) after kaolin injection (Kaolin) and 10, 30, and 60 days after treatment (ZnSO~4~). The orange shaded circle indicates the same animal showing in (**A**). (**C**) Same as (**B**) but for ICP during locomotion. Comparison of ICP during locomotion for aCSF and kaolin injected mice (t(4) = 5.88, p=0.0042, n = 3 for each group, ttest2). (**D**) Same as (**B**) but for stationary (resting) periods in the 2 min immediately after the cessation of isoflurane. (**B--D**) No statistically significant differences were observed between ZnSO~4~-treated and control animal at rest or during locomotion for all treatment durations ([Table 2](#table2){ref-type="table"}). (**E**) Top panel: A decalcified and SeeDB-cleared spinal column after a cisterna magna EB injection. Bottom panel: Red channel only displaying the trace (yellow line) used for quantifying pixel intensity. Scale bar 2 mm. (**F**) Vehicle (top) and 10 days after ZnSO~4~ treatment (bottom) decalcified and SeeDB cleared spinal columns after cisterna magna EB injection. (**G**) Trace obtained and graphed to display dye intensity of EB along the spinal column (distance) quantified after cisterna magna injections. (**H**) Comparisons of the distance of dye movement along the spinal column after an EB cisterna magna injection in mice intranasally treated with vehicle or ZnSO~4~, 2 (t(5) = 0.6921, p=0.5197, n = 3 vehicle and n = 4 treated, ttest2), 10 (t(12) = 5.069, p=0.00028, n = 8 vehicle and n = 6 treated, ttest2), and 30 days (t(9) = 4.571, p=0.00134, n = 3 vehicle and n = 8 treated, ttest2), after treatment. Mean ± standard deviation plotted. \*p≤0.05 \*\*p≤0.01 \*\*\*p≤0.001.](elife-44278-fig10){#fig10}

We found that 2 days after kaolin injections into the cisterna magna ICP significantly increased during locomotion ([Table 2](#table2){ref-type="table"}) compared to aCSF controls ([Figure 10B--C](#fig10){ref-type="fig"}), but not during rest. No statistically significant difference was observed in ZnSO~4~-treated mice at rest or during locomotion as compared to the vehicle controls ([Figure 10B--C](#fig10){ref-type="fig"}) measured 10, 30, and 60 days after treatment ([Table 2](#table2){ref-type="table"}). Additionally, there was no difference between the groups' ICP immediately after isoflurane cessation and before the animal regained consciousness ([Figure 10D](#fig10){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). Despite the blockage of the nasal CSF outflow pathway, ICP did not increase. This suggests that an alternate outflow route is taken and/or CSF production is decreased.

10.7554/eLife.44278.021

###### Mixed model ANOVA statistics for intracranial pressure (ICP) measurements.

For each time point, statistics were calculated for the comparison of the vehicle and treated animal groups. d.o.f. = degrees of freedom.

  Mixed model ANOVA vehicle vs. ZnSO~4~ treated                                            
  ----------------------------------------------- ------- -------- ----------- ------ ---- --------
  10 day                                          11      10       treatment   1.26   37   0.268
   locomotion                                     7.95    0.0077                           
   isoflurane                                     3.38    0.0827                           
  30 day                                          4       4        treatment   3.3    13   0.0922
   locomotion                                     7.32    0.018                            
   isoflurane                                     0.57    0.4786                           
  60 day                                          4       3        treatment   1.7    11   0.2183
   locomotion                                     11.47   0.0061                           
   isoflurane                                     0.58    0.4812                           

Decreased CSF movement down the spinal column following OSN ablation {#s2-10}
--------------------------------------------------------------------

A block in CSF drainage accompanied by no change in ICP implies either a compensatory *decrease* in CSF production or an increase in outflow along other pathways, such as the spinal column. To distinguish between these two hypotheses, we examined the spinal columns after a cisterna magna injection of EB into mice treated with intranasal ZnSO~4~ or vehicle. Since the cisterna magna is 'upstream' from all outflow pathways, including the spinal column, if there is a compensatory increase in the outflow of CSF via the spinal pathway, we would expect dye injected into the cisterna magna to move further down the spinal columns of mice with olfactory nerve ablations as compared to vehicle controls. Conversely, if the CSF production is *reduced* to compensate for the loss of the nasal CSF outflow pathway, we would expect to see a reduction in dye movement down the spinal columns. To differentiate these two possibilities, we extracted the spinal columns and cleared them using SeeDB ([@bib65]; [@bib52]) after EB cisterna magna injections. We quantified the distance the dye traveled along the dorsal side of the spinal column for both vehicle and ZnSO~4~ treated animals, 2, 10, and 30 days after treatment ([Figure 10E--G](#fig10){ref-type="fig"}). While no significant difference between the vehicle and ZnSO~4~ treatment groups in the distance of dye traveled 2 days after treatment was observed, a significant decrease in the distance traveled was observed for both 10 and 30 days after treatment ([Figure 10H](#fig10){ref-type="fig"}). Our results show that in response to the disruption of the nasal outflow pathway there was a decrease in CSF flow down the spinal cord.

Discussion {#s3}
==========

Utilizing histology, microCT imaging, physiology, and tracer dye injections, we investigated the anatomical basis of CSF outflow through the CP into the nasal cavity. The foramina will permit the flow of fluid out of the brain through the intercellular space between OSN axons, blood vessels, and LYVE1^+^ vessels traversing through them. We observed a highly stereotyped pattern in the positioning of the major foramina across mice. It is tempting to speculate that the routes of the OSNs are predisposed to go through either the dorsal or ventral foramina depending on their receptor group and target glomeruli ([@bib17]; [@bib44]; [@bib102]). We found that aquaporin-1 (AQP1) was localized to the olfactory bulb and nerve junction and lining the foramina of the CP, instead of aquaporin-4 (AQP4), which is the dominant water channel in the CNS ([@bib89]). We disrupted CSF drainage through the CP (as well as along the spinal column) by ablating the OSNs. Interestingly, instead of a rise in ICP as would be expected due to a blockage of CSF drainage into the nasal cavity, we observed no change in ICP. This could not be explained by an increase in drainage of CSF down the spinal cord pathway, as we observed a similar reduction in CSF flow down this pathway following ZnSO~4~ treatment. We can think of two non-mutually exclusive possibilities that could explain the lack of ICP rise when an outflow pathway is blocked. The first is that other drainage pathways become engaged and/or reduce their outflow resistance to compensate for the blockage of the cribriform plate outflow. In addition to providing enough drainage to prevent ICP rise, the CSF flow dynamics would be altered by these outflow resistance changes such that the flow down the spinal cord is decreased. One possible location for outflow increase could be the lymphatics at the skull base ([@bib6]) or along the other nerve bundles that exit the skull ([@bib131]; [@bib66]; [@bib15]). A re-routing of CSF flow in a more rostral direction would account for the decreased flow down the spinal cord. Some outflow pathways have thresholds for opening ([@bib130]), and these might become engaged following ZnSO~4~ treatment. The second possibility could be a decrease in the production of CSF. CSF production is not a passive process, but rather one under active neural control ([@bib76]; [@bib40]; [@bib124]). As ICP needs to be maintained within a healthy range, there are likely homeostatic processes that sense ICP, and cause compensatory increases or decreases in CSF production, similar to other mechanosensory processes in other organs of the body ([@bib125]; [@bib50]). A potential mechanism mediating this feedback is mechanically sensitive ASIC3 channels, which are expressed in the ventricles ([@bib59]), and are sensitive to changes in pressure that are physiologically relevant to ICP regulation. Pathological elevations of ICP due to trauma produce a rise in systemic blood pressure and a decrease in heart rate, known as the Cushing response ([@bib53]; [@bib35]), showing the brain has a way of sensing ICP ([@bib53]), and pressure-sensitive brain regions mediating these responses have been identified ([@bib53]; [@bib35]). A similar response may be occurring in the choroid plexus to compensate for the decreased CSF drainage we observe after ZnSO~4~ treatment, thus, avoiding the rise in ICP that is normally associated with a decrease in CSF drainage ([@bib76]; [@bib40]). Neither of these two possibilities excludes the other, and from the experiments performed here, we are unable to differentiate between these two possibilities.

Our dye injections were done under anesthesia and the CSF drainage observed may differ in the awake animal. Although these limitations should be considered, since we observed a difference in drainage between the ZnSO~4~- and vehicle-treated mice, this should still be considered a significant decrease in CSF drainage due to OSN ablation. Although our lymphatic mouse model (Lyve1.Cre.GFP mice crossed with Ai6 or Ai14 reporter lines) exhibited some non-lymphatic specific *LYVE1* expression in vascular endothelial cells in the brain, there were also LYVE1^+^ vessels along the olfactory nerve that did not co-label with vascular perfusion markers (FITC-albumin fills or DiI staining) and that absorbed dye injected into the cisterna magna. These vessels are putatively lymphatic vessels that transport CSF out of the cranial cavity. Previous work has shown that there is transport of fluid across the CP ([@bib14]) and acute blockage of the plate (by sealing it with cyanoacrylate glue) blocks transport of radiolabeled albumin ([@bib16]) establishing the CP as a route of CSF drainage, which then drains into the nasal lymphatics ([@bib42]; [@bib131]; [@bib68]; [@bib90]; [@bib79]; [@bib66]; [@bib127]; [@bib80]; [@bib43]; [@bib97]; [@bib30]; [@bib94]; [@bib62]). Our work elucidates the anatomical basis of CSF transport through the CP and its role in CSF turnover, and demonstrates that damage to the olfactory sensory nerves can impair this pathway.

This work provides a possible mechanism for the observed correlations between neurodegeneration, anosmia, and environmental toxins like air pollution. Although olfactory impairment, or anosmia, occurs during normal aging ([@bib37]; [@bib88]), anosmia frequently precedes many neurological disorders ([@bib119]; [@bib120]; [@bib71]; [@bib101]; [@bib139]). Furthermore, studies have shown correlations with the levels of air pollution with olfactory impairment ([@bib3]; [@bib36]; [@bib2]; [@bib58]; [@bib27]) and neurodegenerative disease pathology, such as Alzheimer's disease ([@bib20]; [@bib21]; [@bib22]; [@bib23]; [@bib24]; [@bib25]), although the mechanism behind these correlations is unclear. Anosmia has many causes, such as smoking and head trauma ([@bib36]), and toxin exposure is another source of olfactory deficits. The OSNs are exposed to environmental toxins (such as air pollutants \[[@bib3]\]) in the nasal cavity, causing an increased rate of OSN death. A decrease in the number of OSNs may be increasing the resistance to CSF outflow, triggering a downregulation in CSF production to maintain normal ICP and/or a change in other outflow pathways that alter CSF flow dynamics. Reduced CSF turnover may be a contributing factor to the buildup of toxic metabolites and proteins that cause neurodegenerative disorders.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                               Designation                                                                Source or reference        Identifiers                                                                                Additional\
  (species) or resource                                                                                                                                                                                                                        information
  ------------------------------------------- -------------------------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------ -------------
  Strain, strain background (*M. musculus*)   Strain: C57BL/6J                                                           Jackson Laboratory         Stock No: 000664; RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)   

  Strain, strain background (*M. musculus*)   Strain: LYVE1^Cre.GFP^                                                     Jackson Laboratory         Stock No: 012601; RRID:[IMSR_JAX:012601](https://scicrunch.org/resolver/IMSR_JAX:012601)   

  Strain, strain background (*M. musculus*)   Strain: Ai6 (RCL-ZsGreen)                                                  Jackson Laboratory         Stock No: 007906; RRID:[IMSR_JAX:007906](https://scicrunch.org/resolver/IMSR_JAX:007906)   

  Strain, strain background (*M. musculus*)   Strain: Ai14 (RCL-tdT)-D                                                   Jackson Laboratory         Stock No: 007914; RRID:[IMSR_JAX:007914](https://scicrunch.org/resolver/IMSR_JAX:007914)   

  Strain, strain background (*M. musculus*)   Strain: Swiss Webster (CFW)                                                Charles River              Strain Code: 024;\                                                                         
                                                                                                                                                    RRID:[IMSR_CRL:24](https://scicrunch.org/resolver/IMSR_CRL:24)                             

  Antibody                                    Rabbit polyclonal anti-Aquaporin 1                                         Santa Cruz\                Cat\# sc-20810;\                                                                           IF (1:250)
                                                                                                                         Biotechnology              RRID:[AB_2056824](https://scicrunch.org/resolver/AB_2056824)                               

  Antibody                                    Mouse monoclonal\                                                          Santa Cruz\                Cat\# sc-25287; RRID:[AB_626694](https://scicrunch.org/resolver/AB_626694)                 IF (1:250)
                                              anti-Aquaporin 1                                                           Biotechnology                                                                                                         

  Antibody                                    Goat polyclonal\                                                           Santa Cruz\                Cat\# sc-9882;\                                                                            IF (1:250)
                                              anti-Aquaporin 2                                                           Biotechnology              RRID:[AB_2289903](https://scicrunch.org/resolver/AB_2289903)                               

  Antibody                                    Goat polyclonal\                                                           Santa Cruz Biotechnology   Cat\# sc-9885; RRID:[AB_2227514](https://scicrunch.org/resolver/AB_2227514)                IF (1:250)
                                              anti-Aquaporin 3                                                                                                                                                                                 

  Antibody                                    Mouse monoclonal\                                                          Santa Cruz\                Cat\# sc-32739; RRID:[AB_626695](https://scicrunch.org/resolver/AB_626695)                 IF (1:250)
                                              anti-Aquaporin 4                                                           Biotechnology                                                                                                         

  Antibody                                    Rabbit polyclonal anti-Aquaporin 5                                         Santa Cruz Biotechnology   Cat\# sc-28628; RRID:[AB_2059871](https://scicrunch.org/resolver/AB_2059871)               IF (1:250)

  Antibody                                    Rat monoclonal anti-CD31                                                   Santa Cruz\                Cat\# sc-18916;\                                                                           IF (1:250)
                                                                                                                         Biotechnology              RRID:[AB_627028](https://scicrunch.org/resolver/AB_627028)                                 

  Antibody                                    Mouse monoclonal anti-CD164                                                Santa Cruz Biotechnology   Cat\# sc-271179;\                                                                          IF (1:250)
                                                                                                                                                    RRID:[AB_10613973](https://scicrunch.org/resolver/AB_10613973)                             

  Antibody                                    Mouse monoclonal anti-Oligo1                                               Santa Cruz Biotechnology   Cat\# sc-166257;\                                                                          IF (1:250)
                                                                                                                                                    RRID:[AB_2157524](https://scicrunch.org/resolver/AB_2157524)                               

  Antibody                                    Mouse monoclonal anti-Vimentin                                             Santa Cruz Biotechnology   Cat\# sc-373717; RRID:[AB_10917747](https://scicrunch.org/resolver/AB_10917747)            IF (1:250)

  Antibody                                    Rabbit polyclonal\                                                         Abcam                      Cat\# ab7260; RRID:[AB_10917747](https://scicrunch.org/resolver/AB_10917747)               IF (1:500)
                                              anti-GFAP                                                                                                                                                                                        

  Antibody                                    Rabbit polyclonal anti-MRC1                                                Abcam                      Cat\# ab64693; RRID:[AB_1523910](https://scicrunch.org/resolver/AB_1523910)                IF (1:500)

  Antibody                                    Goat polyclonal\                                                           WAKO                       Cat\# 544--10001-WAKO; RRID:[AB_664696](https://scicrunch.org/resolver/AB_664696)          IF (1:500)
                                              anti-OMP                                                                                                                                                                                         

  Antibody                                    Mouse monoclonal anti-NeuN                                                 Millipore                  Cat\# MAB377; RRID:[AB_2298772](https://scicrunch.org/resolver/AB_2298772)                 IF (1:250)

  Chemical compound, drug                     DiI                                                                        Invitrogen                 Cat\# D282                                                                                 

  Chemical compound, drug                     Rhodamine Phalloidin                                                       Invitrogen                 Cat\# R415                                                                                 (1:1000)

  Chemical compound, drug                     Albumin--fluorescein isothiocyanate conjugate (FITC-albumin)               Sigma                      Cat\# A9771                                                                                

  Chemical compound, drug                     Formic Acid                                                                Sigma                      Cat\# F0507                                                                                

  Chemical compound, drug                     Fructose                                                                   Sigma                      Cat\# F0127                                                                                

  Chemical compound, drug                     Kaolin                                                                     Sigma                      Cat\# K7375                                                                                

  Chemical compound, drug                     α-thioglycerol                                                             Sigma                      Cat\# M1753                                                                                

  Chemical compound, drug                     Dextran, Fluorescein,3000 MW, Anionic, Lysine Fixable (3kDa-FITCDextran)   ThermoFisher Scientific    Cat\# D3306                                                                                

  Chemical compound, drug                     Zinc Sulfate (ZnSO~4~)                                                     ThermoFisher Scientific    Cat\# AC389802500                                                                          

  Chemical compound, drug                     aCSF                                                                       Tocris Bioscience          Cat\# 3525                                                                                 

  Software, algorithm                         Wheel Manager Software                                                     MedAssociates              RRID:[SCR_014296](https://scicrunch.org/resolver/SCR_014296)                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The protocols used in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at the Pennsylvania State University. Mice were maintained on a 12 hr light-dark cycle with ad libitum access to food and water. We used both male and female Swiss Webster (Charles River, Wilmington, MA), C57BL/6J (Jackson Laboratory, Bar Harbor, ME), and LYVE1-GFP or LYVE1-tdtomato mice. We used a total of 294 mice \[60--120 days/29.0 ± 5.8 g\]. Partitioning was: Male/female (137/157), Swiss Webster (239), C57BL/6J (9) and LYVE1 mice (52). All anatomy studies were repeated in at least three mice. Mice used were ages 60--90 days (young adult). 'LYVE1-GFP' mice are the heterozygous offspring of *Lyve1^EGFP-hCre+/+^* (Jackson Laboratory - Stock No: 012601) and Ai6 (RCL-ZsGreen)^+/+^ (Jackson Laboratory - Stock No: 007906) mice. 'LYVE1-tdtomato' mice are the heterozygous offspring of *Lyve1^EGFP-hCre+/+^* (Jackson Laboratory - Stock No: 012601) and Ai14 (Gt(ROSA)26Sor^tm14(CAG-tdTomato)Hze^)^+/+^ (Jackson Laboratory - Stock No: 007914). This breeding scheme was used because the basal fluorescence of GFP in the *Lyve1^EGFP-hCre^* mice is low ([@bib95]). No differences between the sexes were observed, so males and females were pooled. Randomization was used for all animal grouping.

Histology {#s4-1}
---------

Mice were sacrificed via isoflurane overdose and perfused intracardially with heparinized-saline followed by 4% paraformaldehyde, unless otherwise noted. In some cases, the vasculature was labeled with perfusion of dye, FITC-albumin (MilliporeSigma, St. Louis, MO) or DiI (ThermoFisher Scientific, Waltham, MA) using the protocols described in ([@bib121]; [@bib65]), respectively. The heads were fixed in 4% paraformaldehyde for 24 hr, then decalcified for 48 hr in formic acid (4%) solution, and saturated in 30% sucrose for sectioning. Tissue sections of 100 micrometers thick were sectioned on a freezing microtome. Sections were then either stained for immunofluorescence or thionin-nissl. For immunofluorescence, primary antibodies (and their respective dilutions) used on tissue sections were as follows: OMP (WAKO Chemicals U.S.A., Richmond, VA, 1:500), NeuN (MilliporeSigma, 1:250), Aquaporin-1 (Santa Cruz Biotechnology, Dallas, TX, 1:250), Aquaporin-2 (Santa Cruz, 1:250), Aquaporin-3 (Santa Cruz, 1:250), Aquaporin-4 (Santa Cruz, 1:250), Aquaporin-5 (Santa Cruz, 1:250), Oligo1 (Santa Cruz, 1:250), CD164 (Santa Cruz, 1:250), MRC1 (Abcam, Cambridge, United Kingdom, 1:500), CD31 (Santa Cruz, 1:250) and GFAP (Abcam, 1:500). Phalloidin conjugated to rhodamine was used at a 1:1000 dilution (Invitrogen). The following secondary antibodies were purchased from Abcam and used at a 1:500 working dilution: Goat Anti-Rabbit IgG H and L (Alexa Fluor 488), Donkey Anti-Goat IgG H and L (Alexa Fluor 488), Goat Anti-Mouse IgG H and L (Alexa Fluor 488), Donkey Anti-Rabbit IgG H and L (Alexa Fluor 647), Donkey Anti-Goat IgG H and L (Alexa Fluor 647), and Goat Anti-Mouse IgG H and L (Alexa Fluor 647) preabsorbed. All stainings were done in 24 well plates, with one section per well. Sections were first blocked in either 4% goat or donkey serum for 1 hr at room temperature, then incubated in a 4% serum/primary antibody solution overnight at 4°C. Sections were then incubated in a 4% serum/secondary antibody solution for 1 hr at room temperature. Sections were mounted on silane-coated unifrost slides (Azer Scientific, Morgantown, PA), then coverslipped using fluoroshield mounting medium with DAPI (Abcam). Imaging was done on an Olympus Fluoview 1000 confocal, and images were processed in ImageJ (NIH). For thionin-nissl staining, sections were first mounted on silane-coated unifrost slides and allowed to dry overnight in a 37°C incubator. Slides were then immersed in 95% EtOH, 70% EtOH, 50% EtOH, distilled water, thionin-nissl staining solution, 50%, 70% EtOH, 95% EtOH, 100% EtOH, and xylene and coverslipped using Cytoseal (Thermofisher Scientific).

Cisterna magna (CM) injections {#s4-2}
------------------------------

The animal was anesthetized with isoflurane (5% induction, 2% maintenance) in oxygen. The dorsal surface of the head was elevated 8 mm above the back of the animal and the head was tilted downward at an angle of 10 degrees from horizontal. The base of the skull was exposed by an incision, and a fine glass-pipette (\~20 micrometers in diameter for dye injections) or a 26G needle (for kaolin injections) was inserted into the cisterna magna using a stereotaxic instrument (Stoelting, Wood Dale, IL). Either 2.0 µL of 2% Evans blue in aCSF (Tocris Bioscience, Bristol, United Kingdom) or 5.0 µL of 10% solution of 3kDa-FITCDextran in aCSF was infused at a constant rate of 0.2 μL/min using a syringe pump (Harvard Apparatus, Holliston, MA), an infusion rate that does not raise ICP in mice ([@bib137]). After the injection, the animal was sacrificed via isoflurane overdose and perfused for histology ten minutes after the end of the infusion of dye. For kaolin injections, twenty microliters of 250 mg/mL kaolin (MilliporeSigma) in aCSF (Tocris Bioscience) was infused at a constant rate of 5.0 μL/min using a syringe pump (Harvard Apparatus). After the injection, the incision was sutured and the animal was monitored for 2 days until ICP measurements were made.

Olfactory bulb injections {#s4-3}
-------------------------

The animal was anesthetized with isoflurane in oxygen (5% induction, 2% maintenance). The dorsal surface of the skull was exposed by an incision, and a fine glass-pipette was inserted into the right olfactory bulb using a stereotaxic instrument (Stoelting, Wood Dale, IL). One microliter of 5% solution of 3kDa-FITCDextran in aCSF was infused at a constant rate of 0.1 μL/min using a syringe pump (Harvard Apparatus, Holliston, MA), an infusion rate that does not raise ICP in mice ([@bib137]). After the injection, the animal was sacrificed via isoflurane overdose and perfused for histology 10 min after the end of the infusion of dye.

SeeDB clearing of the spinal column {#s4-4}
-----------------------------------

A modified version of the SeeDB protocol ([@bib65]; [@bib52]) was used to clear the spinal column. The spinal columns were decalcified in formic acid (4%) solution for two days. Next, the spinal columns were saturated in a fructose and α-thioglycerol gradient: 20%--8 hr, 40%--12 hr, 60%--24 hr, 80%--24 hr, 100%--48 hr, and SeeDB solution -- 72 hr. Once cleared, the dorsal side of the spinal columns were imaged under a light microscope.

CT imaging of calcified tissue {#s4-5}
------------------------------

Swiss Webster skulls were imaged with a GE v\|tome\|x L 300 high-resolution nano/microCT scanner and C57BL/6J skulls were imaged on an OMNI-X HD600 industrial microCT scanner (Varian Medical Systems, Palo Alto, CA). Scan settings were 100kV, 0.1mA (GE) or 160kV, 0.25 mA. Image stacks were processed and analyzed in Avizo 8. For each skull, a threshold that segmented the calcified and non-calcified tissue was chosen such that the zygotic maxillary suture, which is externally visible by eye, was clearly defined in the segmented image. To validate that the CT images accurately captured the fine details of the CP, in a subset of skulls the cranial vault was removed using a Dremel tool and the CP photographed on a Zeiss StereoDiscovery V8.

Intranasal administration of substances {#s4-6}
---------------------------------------

After the mouse had been rendered unconscious by a brief exposure to isoflurane, 20 µL of ZnSO~4~ (10% in sterile H~2~O) or vehicle control (sterile H~2~O) was administered to the left nare with a blunt 32G needle. The animal was then inverted to allow for excess fluid to exit the nasal cavity. The animals were monitored and weighed daily after treatment. Approximately 4% of animals treated with ZnSO~4~ died within 24 hr of administration.

Quantification of movement of Evans blue (EB) and olfactory bulb size {#s4-7}
---------------------------------------------------------------------

Images were obtained of the turbinates and olfactory bulb post-mortem in midline sagittally-sectioned ZnSO~4~- and vehicle-treated mice using a Zeiss StereoDiscovery V8 with a 2000R scientific CCD camera (QImaging, Surrey, BC Canada) utilizing µManager software ([@bib39]). We used the red channel, in which EB dye appears as a decrease in intensity, for all analyses. To determine analogous sections between vehicle control and ZnSO~4~-treated animals, the anatomy of the hippocampus was used since olfactory bulb degeneration is observed after ZnSO~4~ treatment ([@bib19]). To measure the dye movement into the nasal epithelium, a rectangular ROI (5 mm rostral-caudal and 3 mm dorsal-ventral in extent) was placed with the caudal-dorsal corner located at the inflection point of the dorsal surface of the olfactory bulb. The center of mass, the location of maximal dye concentration (peak) along the rostral caudal axis, and the maximal dye value were quantified and plotted using Matlab. Using ImageJ, olfactory bulb ROIs were manually drawn around the outer edge of the olfactory bulb to quantify olfactory bulb size. The concentration of albumin in CSF is approximately 300 mg/L, (at 70 kDa/mole, this works out to \~4\*10^--6^ moles/liter) and there are 35 microliters CSF in the mouse (implying \~1.4\*10^--10^ moles of albumin total). There are 12--14 Evans blue (Evans blue: 1 mg\*0.02/ (960g/mole)=2\*10^--8^ moles Evans blue) binding sites per albumin, so \~10% of the Evans blue molecules injected will be bound to CSF albumin ([@bib45]; [@bib46]).

For quantifying dye movement along the spinal column, spinal columns were separated from the skull between the C2 and C3 vertebrae, cleared in SeeDB reagents, and photos of the dorsal side of the spinal columns were taken using a Zeiss StereoDiscovery V8 with a 2000R scientific CCD camera (QImaging) utilizing µManager software ([@bib39]) ([Figure 9D](#fig9){ref-type="fig"} top). Using ImageJ, the image was split into red, green, and blue channels, and only the red channel was used for analysis ([Figure 9D](#fig9){ref-type="fig"} bottom). To compensate for the small bends present in the fixed spinal columns, for each spinal column, a line (yellow) was manually drawn along the midline, from the anterior to posterior end ([Figure 9D](#fig9){ref-type="fig"} bottom). The dye intensity was measured along this line as a function of distance traveled down the spinal column ([Figure 9F](#fig9){ref-type="fig"}).

RT-PCR {#s4-8}
------

RNA was extracted from tissue using the Trizol and chloroform method (described in [@bib110]), and converted to cDNA (Thermo Scientific Verso cDNA synthesis Kit). Primers designed in Primer blast for *Klotho,* and *AQP-1*, validated on the kidney, were used to determine mRNA expression levels. Primer sequences: *AQP1*, 5'CATGGTGGAAGCCAGTTCCTT (FOR) and 5'CAGACCAGGGTGTGTAGTGG (REV); *Klotho*, 5'GTGGCCGAGAGAGTTTTGGA (FOR) and 5'GGGGTCTCACCTTTCAGAGC (REV). Primers for *NF-KB* and *RelA* were previously validated ([@bib135]). *NF-KB1*: 5'GAAATTCCTGATCCAGACAAAAAC (FOR) and 5' ATCACTTCAATGGCCTCTGTGTAG (REV). *RelA: 5'*CTTCCTCAGCCATGGTACCTCT (FOR) and 5'CAAGTCTTCATCAGCATCAAACTG (REV). Mouse *GAPDH* was used as a house-keeping gene and loading control: 5'AGGCCGGTGCTGAGTATGTC (FOR) and 5' TGCCTGCTTCACCACCTTCT (REV) (ShineGene Molecular Biotech, Inc).

Intracranial pressure (ICP) measurements {#s4-9}
----------------------------------------

All surgical procedures were under isoflurane anesthesia (5% for induction and 2% for maintenance). A titanium head-bar was attached to the skull with cyanoacrylate glue and dental cement ([@bib38]; [@bib106]) and the skull was covered with a thin layer of cyanoacrylate glue. After 2 days of recovery, the animal was habituated to head fixation on a spherical treadmill for 1 day (for three 30 min sessions). On the day of the ICP experiment (1 day after the habituation), the mouse was anesthetized with isoflurane and a small craniotomy (\~1 mm diameter) was made in the somatosensory cortex. A pressure-measuring catheter (SPR-1000, Millar, Houston, TX) was inserted into the cortex (−1.0 mm dorsal, −1 mm ventral from bregma), and a tight seal was made using Qwik-sil (World Precision Instruments, Sarasota, FL). This surgical procedure took approximately 10 min. The animal was allowed to wake from anesthesia and to freely locomote on the spherical treadmill ([@bib55]; [@bib56]) for 2 hr, during which both ICP and locomotion were recorded simultaneously at 1 kHz (NI USB-6003). To minimize any residual effect of anesthesia on ICP ([@bib49]), we only analyzed data collected more than 1 hr after the cessation of anesthesia for resting ICP data. The first 2 min after surgery and cessation of isoflurane, when the animal was stationary, were used for the 'rest after isoflurane' analysis.

Statistical analysis {#s4-10}
--------------------

Unless noted, all statistical analysis was performed using Matlab (R2015b, MathWorks, Natick, MA), with the Matlab function used (i.e. 'ttest2') is listed. All summary data were reported as the mean ± standard deviation (SD). Normality (Anderson-Darling test, adtest) and of the samples were tested before statistical testing. When the data conform to the normality assumption, difference between treatments were compared using unpaired t-test (ttest2). If the condition of normality was not met, parametric tests (ttest2) were substituted with a non-parametric method (Mann-Whitney U test, ranksum). For comparing the effects of treatment and duration on CSF drainage, two-way ANOVA was used. For the wheel activity data, the K-S test was used. For the ICP data, a mixed model ANOVA test was used. A result was considered significant if p≤0.05 after correcting for multiple comparisons using the Bonferonni correction.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Anatomical basis and physiological role of cerebrospinal fluid transport through the murine cribriform plate\" for consideration by *eLife*. Your article has been reviewed by Ronald Calabrese as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Roxana Carare (Reviewer \#1); Robert G Thorne (Reviewer \#2); Jeff Illif (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a nicely executed study with some very interesting and novel findings related to olfactory nerve -- cribriform plate (CP) -- olfactory mucosa relationships. Overall this study provides important anatomical insight into an understudied region of the skull base which has recently re-emerged interest-wise into the neuro-immunology field owing to the recent detailed characterization of meningeal lymphatic vessels by the Alitalo and Kipnis groups. Arguably the strongest portion of the work relates to the anatomical descriptions of the nerves/vessels/lymphatics/water channels in this key interface region, previously not well described in the rodent. Somewhat weaker are the author\'s ZnSO~4~ nerve ablation experiments because of the difficulty / challenge in interpreting the resulting findings. Still there is a lot of new compelling data here and a novel way of looking at the CSF system.

Essential revisions:

The reviewers were in agreement that the portion of the manuscript dealing with CSF secretion needs to be extensively rewritten. It should be possible for the authors to address the comments that all the reviewers have made while retaining much of the content, not only the anatomical description portion. Specifically, for the functional studies, the authors must account much better for other possibilities and not be so definitive in their conclusions. Particularly the conclusion that lesioning the olfactory path in some way results in a feed-back regulation of CSF secretion. The experiment performed simply isn\'t solid enough to definitively answer that question. The other functional question -- the contribution that drainage down this pathway makes to overall drainage along the cervical lymphatics helps to place the study within the wider experimental context of the field (both historical and current elements), but this experiment is not totally definitive either and must be discussed with care.

Reviewer \#1:

This is an elegant study encompassing novel methodology and demonstrating firstly the exact anatomical features of the cribriform plates and their penetrating structures. Secondly, the authors demonstrate that ablating the olfactory sensory neurons results in the decreased production of CSF with ICP remaining unchanged. My main question is whether the authors could be more specific about the nature of the vessels that express LYVE1- are they arteries or veins and is LYVE1 present also on capillaries.

Reviewer \#2:

This is a nicely executed study with some very interesting and novel findings related to olfactory nerve -- cribriform plate (CP) -- olfactory mucosa relationships. Arguably the strongest portion of the work relates to the anatomical descriptions of the nerves/vessels/lymphatics/water channels in this key interface region, previously not well described in the rodent. Somewhat weaker are the author\'s ZnSO~4~ nerve ablation experiments because of the obvious difficulty / challenge in interpreting the resulting findings. The authors would be wise to revisit some of their conclusions, softening the description and better allowing for alternatives (e.g. statements such as \'one possibility may be that...\' and \'although further work is needed to definitively conclude X, we think it likely that...\' would greatly help their manuscript stand the test of time and not be seen by some specialists in the field as over-reaching in places). Nevertheless, the results are important. So long as some of the interpretations acquire a bit more nuance and care in the strength of conclusions derived from them, the experiments described in this manuscript represent a significant advance for the rapidly growing research area concerned with lymphatic drainage from the brain.

1\) The authors would do well to comment upon and relate their findings to Buck and Axel\'s 2004 Nobel Prize winning studies (superfamily of GPCR odorant receptors) and subsequent related work better identifying zones and projection patterns from the olfactory epithelium to glomeruli in the bulb. For example, do the authors believe that these projections are organized in any special way between the major and smaller foramina that they describe in the manuscript? What do the authors think are the primary differences between the major foramina and smaller, minor foramina that are so consistently represented in the two strains of mice they examined? This is an excellent topic for speculation that the authors somewhat avoid in favor of less wise discussion later in the manuscript over their ablation experiments (see below). However, the possible significance of the anatomical relationships they describe more fully for the first time in the mouse would certainly seem to merit a bit more discussion.

2\) Subsection "Blood vessels traverse the cribriform plate". The authors state in the results that \'blood vessels traverse the CP in the mouse, much like the ethmoidal arteries observed in humans (refs), linking the vascular territories of the nasal epithelia and brain.\' This statement would seem to imply that the ethmoidal artery -- CP relationship has not been described in mice / rodents but there are publications that previously discuss this (e.g., Lochhead and Thorne, 2012). Of some interest and not commented upon is venous drainage. Did the authors identify veins traversing the CP? Is there any link between draining veins of the olfactory mucosa and the olfactory sinus via the CP? The authors should at minimum comment on this, citing what is known from the literature, so that their manuscript provides more complete coverage of the subject area. It is not beyond the scope of what they have studied and described in the manuscript to more fully on these important points. The vascular relationships between the nasal mucosae and brain are quite important clinically; better elaboration of these relationships in the rodent will aid in understanding the relevance (and possible limitations) of rodent models of disease.

3\) Subsection "Aquaporins at the olfactory nerve-bulb interface". AQP1 is described as lining the \'foramina of the CP along the crista galli.\' Several questions arise: did they mean to imply that it is only the smaller foramina and not the major foramina that had this AQP1 expression? Looking at Shields et al., 2010 that identified olfactory ensheathing cells as expressing AQP1, it is not clear if the authors agree that their findings are consistent with that reference or that their AQP1 expression is rather localized to the olfactory nerve fibroblasts that surround axon bundles (and would naturally be in a location lining the outside of foramina; it has been well described that ensheathing cells wrap individual axon bundles and would be more uniformly represented in nerve bundle cross sections, rather than at the peripheral edges; see Kumar et al., 2018 Figure 5E and associated references). The authors should further comment on this. Most importantly, Weller et al., have described in a recent publication (2018) the expression of AQP1 on \'dural border cells\' of the meninges with some discussion about the CP area (e.g., in Figure 1D and F of the 2018 paper). The authors of the current manuscript describe AQP1 as limited to the CP area they describe and the choroid plexus, but this description lacks the real complexity of the fuller picture described in the Weller et al. reference and some of Mollgard\'s prior related work. The authors should consult this literature and more fully elaboration their AQP discussion.

4\) The authors argue in their ablation experiment description (subsection "Ablation of OSNs decreases CSF outflow") that \'because the space between the OSN axons provides a conduit for outflow of CSF and ISF, removing these axons should decrease outflow of CSF.\' However, the opposite might be argued as well. If axons are removed from bundles surrounded by olfactory ensheathing cells, then the space may be filled in, so to speak, by fluid secretion, thus creating effectively larger volume paths for fluid outflow. Perhaps this might be an alternative explanation for the observation that EB outflow to the deep cervical lymph nodes was unchanged in ZnSO~4~-treated animals and for the lack of ICP increase they observed? The authors would do well to flesh out their interpretation in this section of the manuscript far better, allowing for other possibilities. It would seem to be easily argued that the authors results do NOT definitively \'show that in response to the disruption of the nasal outflow pathway... CSF production was decreased\' (subsection "OSN ablation does not affect ICP"), as the authors assert in the closing sentence, simply because CSF production was not directly measured. Inference is quite different from proof! The authors would do well to recognize the countless number of times in science where results looked straightforward in allowing a certain inference at a given time, only to be made to look naïve with subsequent future studies showing a more complex situation. Accordingly, I strongly advise that the statements and related discussion by the authors regarding interpretation of the ZnSO~4~ ablation experiments really need to better reflect this, more fully allowing for other interpretations and possibilities, not least that the physiology may be much more complicated than their description allows for (see comments in opening summary). Such a revision will not require a major change or rewrite, only the addition of a few more carefully and thoughtfully placed qualifiers and perhaps some further thought about alternatives. The Discussion section accomplishes this balancing act better than the Results section, as currently written. The Results section would be greatly improved by making this strongly advised change.

Reviewer \#3:

The study by Norwood and colleagues uses several imaging approaches to define the anatomical landscape of the cribriform plate and nasal turbinates; then using fluorescent tracers and chemical ablation of the olfactory nerves, they demonstrate that this ablation appears to reduce CSF efflux across the cribriform plate, reportedly associated with changes in CSF secretion. Overall this study provides important anatomical insight into an understudied region of the skull base which has recently re-emerged interest-wise into the neuro-immunology field owing to the recent detailed characterization of meningeal lymphatic vessels by the Alitalo and Kipnis groups. While the anatomical descriptions of these barriers appears to be conducted well and with care, and are themselves a useful addition to the field, the functional elements of the study that seek to address what this efflux pathway is doing, and what the consequences of its lesioning are, are generally underdeveloped and should be strengthened to improve the value of the study to the field. Most critical items follow:

Effect of nerve lesion on CSF secretion and reabsorption. By plotting CSF tracer distribution along the neuroaxis, the authors note that distribution shifts away from the anterior portion with olfactory nerve ligation, although distribution down the spinal cord is also reduced. From this, a reduction in CSF secretin is inferred, supported by unchanged ICP measurements in awake-behaving animals.

\- A reduced CSF secretion would be very interesting. CSF secretion should be evaluated directly using a gold-standard ventriculo-cisternal tracer perfusion method.

\- ICP monitoring was conducting in waking, moving animals, while tracer studies were conducted in anesthetized animals. Either ICP monitoring should be done under the same physiological state as the tracer studies, or vise-versa.

\- The authors note no change in the lymphatic vasculature at the cribriform plate with Zn ablation. But that tracer movement across is reduced. Is overall CSF drainage down the cervical lymphatic trunks altered? If so, then this would support their contention that altering cribriform plate efflux alters CSF dynamics, while no change in CSF tracer efflux along the lymphatic trunks would argue that compensatory efflux along another route is occurring.

\- Lastly -- does the nerve lesion result in any neuroinflammation -- either glial changes with the parenchymal compartment, or immune cell changes in the meningeal or CSF compartments? Such changes might be predicted to alter CSF tracer dynamics and distribution and should be ruled in or out.

Tracer uptake into lymphatic vessels. The presence of lymphatic vessels at the cribriform plate is described, and the results of the present study clearly are relevant to how meningeal lymphatic vessels throughout the cranium, including in the skull base and in association with dural sinuses function -- what their relative contribution to CSF solute efflux are, and how they are impacted by the intervention to lesion olfactory nerves. Some questions remain on this that are important for placing the significance of this efflux pathway relative to these others.

\- Do CSF tracers concentrate in the cribriform plate lymphatic vessels? Or is there tracer simply permeating this structure, which also has lymphatic vessels within it? Do the authors note uptake of tracer into dural sinus-associated lymphatic vessels (again -- concentration within them, not simply labeling of meninges).

\- Does uptake into non-cribriform lymphatic vessels change with nerve lesion? This would be very interesting question to answer regardless of the outcome and would be related to overall lymphatic efflux issue noted above.

10.7554/eLife.44278.025

Author response

> Summary:
>
> This is a nicely executed study with some very interesting and novel findings related to olfactory nerve -- cribriform plate (CP) -- olfactory mucosa relationships. Overall this study provides important anatomical insight into an understudied region of the skull base which has recently re-emerged interest-wise into the neuro-immunology field owing to the recent detailed characterization of meningeal lymphatic vessels by the Alitalo and Kipnis groups. Arguably the strongest portion of the work relates to the anatomical descriptions of the nerves/vessels/lymphatics/water channels in this key interface region, previously not well described in the rodent. Somewhat weaker are the author\'s ZnSO~4~ nerve ablation experiments because of the difficulty / challenge in interpreting the resulting findings. Still there is a lot of new compelling data here and a novel way of looking at the CSF system.
>
> Essential revisions:
>
> The reviewers were in agreement that the portion of the manuscript dealing with CSF secretion needs to be extensively rewritten. It should be possible for the authors to address the comments that all the reviewers have made while retaining much of the content, not only the anatomical description portion. Specifically, for the functional studies, the authors must account much better for other possibilities and not be so definitive in their conclusions. Particularly the conclusion that lesioning the olfactory path in some way results in a feed-back regulation of CSF secretion. The experiment performed simply isn\'t solid enough to definitively answer that question. The other functional question -- the contribution that drainage down this pathway makes to overall drainage along the cervical lymphatics helps to place the study within the wider experimental context of the field (both historical and current elements), but this experiment is not totally definitive either and must be discussed with care.

In response to the reviewer's comments, we removed the text claiming that ZnSO~4~ treatment causes a decrease in CSF production. We have added text to the Discussion section discussing other possible explanations, and a statement that our experiments cannot distinguish between the possible origins of lack of an ICP increase. The Discussion section now reads:

"Interestingly, instead of a rise in ICP as would be expected due to a blockage of CSF drainage into the nasal cavity, we observed no change in ICP. This could not be explained by an increase in drainage of CSF down the spinal cord pathway, as we observed a similar reduction in CSF flow down this pathway following ZnSO~4~ treatment. We can think of two non-mutually exclusive possibilities that could explain the lack of ICP rise when an outflow pathway is blocked. The first is that other drainage pathways become engaged and/or reduce their outflow resistance to compensate for the blockage of the cribriform plate outflow. In addition to providing enough drainage to prevent ICP rise, the CSF flow dynamics would be altered by these outflow resistance changes such that the flow down the spinal cord is decreased. One possible location for outflow increase this could by the lymphatics at the skull base (Antila et al., 2017) or along the other nerve bundles that exit the skull (Bradbury and Cole, 1980; Kida, Pantazis and Weller, 1993; Kida et al., 1994). A re-routing of CSF flow in a more rostral direction would account for the decreased flow down the spinal cord. Some outflow pathways have thresholds for opening (Welch and Friedman 1960), such as arachnoid villi, and these might become engaged following ZnSO~4~ treatment. While arachnoid villi have been described in primates and other species, there are no definitive anatomical studies in the mouse. The second possibility could be a decrease in the production of CSF. CSF production is not a passive process, but rather one under active neural control (Lindvall, Edvinsson and Owman, 1978; Edvinsson and Lindvall, 1978; Tuor et al., 1990). As ICP needs to be maintained within a healthy range, there are likely homeostatic processes that sense ICP, and cause compensatory increases or decreases in CSF production, similar to other mechanosensory processes in other organs of the body (Umans and Liberles, 2018; Sarah-Jane et al., 2018). A potential mechanism mediating this feedback is mechanically-sensitive ASIC3 channels, which are expressed in the ventricles (Jalalvand et al., 2018), and are sensitive to changes in pressure that are physiologically relevant to ICP regulation. Pathological elevations of ICP due to trauma produce a rise in systemic blood pressure and a decrease in heart rate, known as the Cushing response (Hoff and Reis, 1970; Doba and Reis, 1972), showing the brain has a way of sensing ICP (Hoff and Reis, 1970), and pressure-sensitive brain regions mediating these responses have been identified (Doba and Reis, 1972; Hoff and Reis, 1970). A similar response may be occurring in the choroid plexus to compensate for the decreased CSF drainage we observe after ZnSO~4~ treatment, thus, avoiding the rise in ICP that is normally associated with a decrease in CSF drainage (Lindvall, Edvinsson and Owman, 1978; Edvinsson and Lindvall, 1978). Neither of these two possibilities excludes the other, and from the experiments performed here, we are unable to differentiate between these two possibilities."

> Reviewer \#1:
>
> This is an elegant study encompassing novel methodology and demonstrating firstly the exact anatomical features of the cribriform plates and their penetrating structures. Secondly, the authors demonstrate that ablating the olfactory sensory neurons results in the decreased production of CSF with ICP remaining unchanged. My main question is whether the authors could be more specific about the nature of the vessels that express LYVE1- are they arteries or veins and is LYVE1 present also on capillaries.

To answer this question, we stained brain sections from LYVE1-Ai6 mice with rhodamine-conjugated phalloidin. We observed LYVE1 expression along both arteries and capillaries in the mouse cortex. Results of these experiments were added to Figure 3---figure supplement 2 and the subsection "Lymphatic vessels traverse the cribriform plate".

> Reviewer \#2:
>
> This is a nicely executed study with some very interesting and novel findings related to olfactory nerve -- cribriform plate (CP) -- olfactory mucosa relationships. Arguably the strongest portion of the work relates to the anatomical descriptions of the nerves/vessels/lymphatics/water channels in this key interface region, previously not well described in the rodent. Somewhat weaker are the author\'s ZnSO~4~ nerve ablation experiments because of the obvious difficulty / challenge in interpreting the resulting findings. The authors would be wise to revisit some of their conclusions, softening the description and better allowing for alternatives (e.g. statements such as \'one possibility may be that...\' and \'although further work is needed to definitively conclude X, we think it likely that...\' would greatly help their manuscript stand the test of time and not be seen by some specialists in the field as over-reaching in places). Nevertheless, the results are important. So long as some of the interpretations acquire a bit more nuance and care in the strength of conclusions derived from them, the experiments described in this manuscript represent a significant advance for the rapidly growing research area concerned with lymphatic drainage from the brain.
>
> 1\) The authors would do well to comment upon and relate their findings to Buck and Axel\'s 2004 Nobel Prize winning studies (superfamily of GPCR odorant receptors) and subsequent related work better identifying zones and projection patterns from the olfactory epithelium to glomeruli in the bulb. For example, do the authors believe that these projections are organized in any special way between the major and smaller foramina that they describe in the manuscript? What do the authors think are the primary differences between the major foramina and smaller, minor foramina that are so consistently represented in the two strains of mice they examined? This is an excellent topic for speculation that the authors somewhat avoid in favor of less wise discussion later in the manuscript over their ablation experiments (see below). However, the possible significance of the anatomical relationships they describe more fully for the first time in the mouse would certainly seem to merit a bit more discussion.

The question regarding the anatomical relationships and patterns of the projections through the major and minor foramina could be addressed by using markers (either genetic or immunohistochemically) for specific olfactory receptor proteins and histologically determining if the axons of a specific receptor type exhibited a stereotyped pattern or preference for foramina. We did not check for any such relationships or patterns, but have added the following to the Discussion section:

"We observed a highly stereotyped pattern in the positioning of the major foramina across mice. It is tempting to speculate that the OSN axons are predisposed to go through either the dorsal or ventral foramina depending on their receptor group and target glomeruli (Buck and Axel, 1991; Feinstein and Mombaerts, 2004; Rodriguez-Gil et al., 2010)."

> 2\) Subsection "Blood vessels traverse the cribriform plate". The authors state in the results that \'blood vessels traverse the CP in the mouse, much like the ethmoidal arteries observed in humans (refs), linking the vascular territories of the nasal epithelia and brain.\' This statement would seem to imply that the ethmoidal artery -- CP relationship has not been described in mice / rodents but there are publications that previously discuss this (e.g., Lochhead and Thorne, 2012).

We thank the reviewer for bringing this literature to our attention. The relationship of the vascular territories of the nasal epithelia and brain were already very well documented in (Lochhead and Thorne, 2012a). This comparison was used to emphasize the similarities of the anatomy of this area between humans and mice and the usefulness and applicability of using the mouse as a model for this system. We have added the Lochhead and Thorne reference and other references, so the section now reads:

"These results are consistent with previous work showing blood vessels traverse the CP in the rodent (Lochhead and Thorne, 2012b), much like the ethmoidal arteries and veins observed in humans (Knudsen, Andersen and, Krag 1989; Yang et al., 2009; Souza et al., 2009; Tsutsumi, Ono and Yasumoto, 2016; Tsutsumi et al., 2019; Lochhead and Thorne, 2012b), linking the vascular territories of the nasal epithelia and brain."

> Of some interest and not commented upon is venous drainage. Did the authors identify veins traversing the CP? Is there any link between draining veins of the olfactory mucosa and the olfactory sinus via the CP? The authors should at minimum comment on this, citing what is known from the literature, so that their manuscript provides more complete coverage of the subject area. It is not beyond the scope of what they have studied and described in the manuscript to more fully on these important points. The vascular relationships between the nasal mucosae and brain are quite important clinically; better elaboration of these relationships in the rodent will aid in understanding the relevance (and possible limitations) of rodent models of disease.

Whether the vessels traversing the cribriform plate were arteries or veins cannot be definitively concluded from our experiments. The vessels were identified by FITC-albumin or DiI cardiovascular fills, neither of which provides any contrast between arteries and veins. The section on the cribriform plate traversing vessels now reads:

"We first looked at whether blood vessels traversed the CP by either filling the vessel lumen with FITC-albumin (Tsai et al., 2009), or labeling the endothelial cells by perfusing the vasculature with the fluorescent lipophilic dye DiI (Li et al., 2008). Note that we cannot distinguish between arteries or veins using these methods."

> 3\) Subsection "Aquaporins at the olfactory nerve-bulb interface". AQP1 is described as lining the \'foramina of the CP along the crista galli.\' Several questions arise: did they mean to imply that it is only the smaller foramina and not the major foramina that had this AQP1 expression?

We did not observe any AQP1 expression lining the major foramina of the cribriform plate, and have clarified the relevant section to read:

"We observed high levels of AQP1 expression on the olfactory nerve layer, down to the glomeruli, and in the lamina propria of the neuroepithelium at both the medial (Figure 2F-G) and dorsal (Figure 2H-K) junctions of the olfactory bulb and nerve, but not lining the major foramina."

> Looking at Shields et al., 2010 that identified olfactory ensheathing cells as expressing AQP1, it is not clear if the authors agree that their findings are consistent with that reference or that their AQP1 expression is rather localized to the olfactory nerve fibroblasts that surround axon bundles (and would naturally be in a location lining the outside of foramina; it has been well described that ensheathing cells wrap individual axon bundles and would be more uniformly represented in nerve bundle cross sections, rather than at the peripheral edges; see Kumar et al., 2018 Figure 5E and associated references). The authors should further comment on this.

The localization of expression and pattern of staining of AQP1 along the olfactory bulb observed would support previous findings that olfactory ensheathing cells along the periphery of the olfactory bulb express AQP1 (Shields et al., 2010). Expression of AQP1 in fibroblasts was checked by staining with Vimentin (expressed by fibroblasts) in the foramina of the cribriform plate but co-localization of AQP1 and vimentin expression was not observed. Based on these results, we believe the cells expressing AQP1 that surround the axon bundles might be olfactory ensheathing cells (OECs). We have added figures showing AQP1 and Vimentin antibody staining in the cribriform plate to Figure 2---figure supplement 1J-K.

Text below was added to the Results section:

"We observed high levels of AQP1 expression on the olfactory nerve layer down to the glomeruli, as observed previously (Shields et al., 2010), and in the lamina propria of the neuroepithelium at both the medial (Figure 2F-G) and dorsal (Figure 2H-K) junctions of the olfactory bulb and nerve. AQP1 was also observed lining the foramina of the CP along the crista galli (Figure 2L, N-O) but did not co-label with Vimentin-positive fibroblasts (Figure 2---figure supplement 1J-K). Based on previous reports (Au, Treloar and Greer, 2002; Kumar et al., 2018) and our own results, we hypothesize that these cells might be olfactory ensheathing cells (OECs)."

> Most importantly, Weller et al., have described in a recent publication (2018) the expression of AQP1 on \'dural border cells\' of the meninges with some discussion about the CP area (e.g., in Figure 1D and f of the 2018 paper). The authors of the current manuscript describe AQP1 as limited to the CP area they describe and the choroid plexus, but this description lacks the real complexity of the fuller picture described in the Weller et al. reference and some of Mollgard\'s prior related work. The authors should consult this literature and more fully elaboration their AQP discussion.

Reviewer \#2 brings up a good point about AQP1 expression in development that we overlooked. Embryonically, AQP1 expression begins around E13 (in the rat) and its pattern and sequence of development is maintained throughout many mammals, including humans (Johansson et al., 2005). Interestingly, AQP1 expression was also observed in dural border cells of the embryonic rat dura (Weller et al., 2018). Text below was added to the Results section:

"We first looked at the expression of aquaporin-1 (AQP1), as it has been shown that expression in the CNS begins early (Johansson et al., 2005; Weller et al., 2018), and is required in adulthood to maintain CSF production by the choroid plexus (Oshio et al., 2005). Interestingly, previous work has also shown that AQP1 is expressed along the periphery of the olfactory bulb in neonatal mice (Shields et al., 2010), and there is a high level of expression of AQP1, 3, and 5, within the nasal cavity (Ablimit et al., 2006)."

> 4\) The authors argue in their ablation experiment description (subsection "Ablation of OSNs decreases CSF outflow") that \'because the space between the OSN axons provides a conduit for outflow of CSF and ISF, removing these axons should decrease outflow of CSF.\' However, the opposite might be argued as well. If axons are removed from bundles surrounded by olfactory ensheathing cells, then the space may be filled in, so to speak, by fluid secretion, thus creating effectively larger volume paths for fluid outflow. Perhaps this might be an alternative explanation for the observation that EB outflow to the deep cervical lymph nodes was unchanged in ZnSO~4~-treated animals and for the lack of ICP increase they observed?

There are two possible outcomes from our ablation experiment: either ablation of the OSNs creates a hole, or the removal of the OSNs leads to sealing of the opening. Since we did not observe flow into the nasal cavity, there is unlikely to be a hole. Additionally, larger volume paths were not observed, since there were large decreases in EB and fluorescein in the nasal cavity after ZnSO~4~ treatment (Figure 7 and Figure 7---figure supplement 1). An alternative explanation to the unchanged EB outflow to the deep cervical lymph nodes is that the EB dye may be entering other outflow pathways at the skull base, such as the optic nerves or lymphatics in the spinal column (see response to "Essential revisions").

> The authors would do well to flesh out their interpretation in this section of the manuscript far better, allowing for other possibilities. It would seem to be easily argued that the authors results do NOT definitively \'show that in response to the disruption of the nasal outflow pathway... CSF production was decreased\' (subsection "OSN ablation does not affect ICP"), as the authors assert in the closing sentence, simply because CSF production was not directly measured. Inference is quite different from proof!

The reviewer brings up a very good point and we have addressed this above.

> The authors would do well to recognize the countless number of times in science where results looked straightforward in allowing a certain inference at a given time, only to be made to look naïve with subsequent future studies showing a more complex situation. Accordingly, I strongly advise that the statements and related discussion by the authors regarding interpretation of the ZnSO~4~ ablation experiments really need to better reflect this, more fully allowing for other interpretations and possibilities, not least that the physiology may be much more complicated than their description allows for (see comments in opening summary). Such a revision will not require a major change or rewrite, only the addition of a few more carefully and thoughtfully placed qualifiers and perhaps some further thought about alternatives. The Discussion section accomplishes this balancing act better than the Results section, as currently written. The Results section would be greatly improved by making this strongly advised change.

We have rewritten the Discussion section to cover alternate possibilities (see response to "Essential revisions" above).

> Reviewer \#3:
>
> The study by Norwood and colleagues uses several imaging approaches to define the anatomical landscape of the cribriform plate and nasal turbinates; then using fluorescent tracers and chemical ablation of the olfactory nerves, they demonstrate that this ablation appears to reduce CSF efflux across the cribriform plate, reportedly associated with changes in CSF secretion. Overall this study provides important anatomical insight into an understudied region of the skull base which has recently re-emerged interest-wise into the neuro-immunology field owing to the recent detailed characterization of meningeal lymphatic vessels by the Alitalo and Kipnis groups. While the anatomical descriptions of these barriers appears to be conducted well and with care, and are themselves a useful addition to the field, the functional elements of the study that seek to address what this efflux pathway is doing, and what the consequences of its lesioning are, are generally underdeveloped and should be strengthened to improve the value of the study to the field. Most critical items follow:
>
> Effect of nerve lesion on CSF secretion and reabsorption. By plotting CSF tracer distribution along the neuroaxis, the authors note that distribution shifts away from the anterior portion with olfactory nerve ligation, although distribution down the spinal cord is also reduced. From this, a reduction in CSF secretin is inferred, supported by unchanged ICP measurements in awake-behaving animals.
>
> \- A reduced CSF secretion would be very interesting. CSF secretion should be evaluated directly using a gold-standard ventriculo-cisternal tracer perfusion method.

While this has been used as a gold-standard for measuring CSF secretion, the results are often times variable, even in much larger animals than the mouse. Based on this variability and the challenging nature of this method in the mouse, we did not perform these experiments. We hope that future technical innovations make these experiments more feasible in a mouse model.

> \- ICP monitoring was conducting in waking, moving animals, while tracer studies were conducted in anesthetized animals. Either ICP monitoring should be done under the same physiological state as the tracer studies, or vise-versa.

The reviewer brings up a good point. In response to the reviewer's point, we have added ICP measurements made at the end of the surgery in the two minutes after the cessation of isoflurane but before the animal regained consciousness (Figure 10D, Supplementary file 2). The concentration of isoflurane in the mouse during this period will still be very high. In general, the ICP was higher during this period, consistent with previous results that show isoflurane increases resting ICP (Gao and Drew, 2016). We find that there is no difference between the ICP of the different groups immediately after isoflurane. While this is not the optimal experiment, it is the best we can do without repeating this series of experiments in anesthetized animals. The text below was added to the Results section:

"No statistically significant difference was observed in ZnSO~4~ treated mice at rest or during locomotion as compared to the vehicle controls (Figure 10B-C) measured 10, 30, and 60 days after treatment (Supplementary file 2). Additionally, there was no difference between the groups' ICP immediately after isoflurane cessation and before the animal regained consciousness (Figure 10D, Supplementary file 2)."

> \- The authors note no change in the lymphatic vasculature at the cribriform plate with Zn ablation. But that tracer movement across is reduced. Is overall CSF drainage down the cervical lymphatic trunks altered? If so, then this would support their contention that altering cribriform plate efflux alters CSF dynamics, while no change in CSF tracer efflux along the lymphatic trunks would argue that compensatory efflux along another route is occurring.

We were unable to quantitatively measure the Evans blue signal in the lymph nodes in the neck optically. Future experiments using radioactive tracers and collection of lymphatic fluid flow should be better positioned to quantify any changes.

> \- Lastly -- does the nerve lesion result in any neuroinflammation -- either glial changes with the parenchymal compartment, or immune cell changes in the meningeal or CSF compartments? Such changes might be predicted to alter CSF tracer dynamics and distribution and should be ruled in or out.

To address the reviewer's question, we assayed glial changes in the cortex and inflammation marker mRNA expression in the choroid plexus both 2 and 10 days after ZnSO~4~ treatment. However, no changes in any of the inflammation markers was observed. This has been added to Figure 6---figure supplement 2, and the following was added to the Results section:

"We then assayed mRNA levels in the choroid plexus and GFAP expression in the cortex to look for immune responses to ZnSO~4~ treatment. AQP1, expressed by epithelial cells in the choroid plexus, is involved in CSF production (Oshio et al., 2005). Klotho is a protein involved in suppressing aging and is significantly elevated in the CSF of Alzheimer's disease patients (Kuro-o et al., 1997; Semba et al., 2014). The NF-κβ pathway is involved in the choroid plexus acute-phase response to peripheral inflammation (Marques et al., 2009), and RelA is required for NF- κβ activation (Chen and Greene 2004). GFAP is a hallmark marker for astrocytes and is upregulated as part of an inflammatory response (Sofroniew, 2009). However, we found no appreciable changes in mRNA levels or GFAP expression (Figure 6 ---figure supplement 2) 2 or 10 days after ZnSO~4~ treatment indicating there is no inflammatory response in the cranial cavity following treatment."

> Tracer uptake into lymphatic vessels. The presence of lymphatic vessels at the cribriform plate is described, and the results of the present study clearly are relevant to how meningeal lymphatic vessels throughout the cranium, including in the skull base and in association with dural sinuses function -- what their relative contribution to CSF solute efflux are, and how they are impacted by the intervention to lesion olfactory nerves. Some questions remain on this that are important for placing the significance of this efflux pathway relative to these others.
>
> \- Do CSF tracers concentrate in the cribriform plate lymphatic vessels? Or is there tracer simply permeating this structure, which also has lymphatic vessels within it?

We observe dye throughout the tissue in the major foramina, which has LYVE1^+^-vessels in it. Though the dye co-localizes within these vessels, it does not concentrate in it. We have clarified this in the text:

"3kDa-FITCDextran was observed draining into the nasal cavity along the olfactory nerve (Figure 5D-F), and co-localizing with LYVE1+ vessels along the olfactory nerve (Figure 5G-I), though the dye did not appear to be concentrated in the LYVE1+ vessels."

> Do the authors note uptake of tracer into dural sinus-associated lymphatic vessels (again -- concentration within them, not simply labeling of meninges).
>
> \- Does uptake into non-cribriform lymphatic vessels change with nerve lesion? This would be very interesting question to answer regardless of the outcome and would be related to overall lymphatic efflux issue noted above.

In preliminary experiments in untreated mice, we did not see cisterna magna-injected dye in the dural sinus-associated lymphatic vessels or other locations in the dura using our dye-infusion protocol. We did not check the dural sinus-associated lymphatic vessels in ZnSO~4~-treated mice. The presence of the dye in the dural likely depends on the specifics of the injection and perfusion protocol (timing, etc.), so we are hesitant to generalize our results.
